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I worked for my PhD in Prof. Irma Dianzani’s Lab, at the Department of Health Sciences in 
Novara working on Diamond-Blackfan anemia (DBA). DBA is an inherited red blood cell 
aplasia that is usually diagnosed in early infancy. Patients with DBA exhibit a macrocytic 
normochromic anaemia and reticulocytopenia. Elevated fetal haemoglobin levels (HbF) and 
elevated erythrocyte adenosine deaminase (eADA) activity are other features of DBA. 
Bone marrow failure (BM) is due to the loss of erythroid progenitors (BFU-E and CFU-E) 
that is evident by colony assay. The occurence of other inherited bone marrow failure 
syndromes that share clinical symptoms make DBA a diagnosis of exclusion. 
DBA was the first disease associated with defective ribosome biogenesis and rRNA 
processing. Heterozygous mutations in one of 17 ribosomal protein (RP) genes, both of the 
small (RPS) and the large (RPL) subunit, have been found in about 65% of patients. RP 
mutations may be inherited with an autosomal dominant pattern or may arise de novo. 
Recently, mutations in GATA1 and TSR2 have also been found in rare patients with DBA 
showing that also non-RP genes can cause DBA. The genes affected in approximately 35% 
of suspected DBA patients remain unknown leaving a degree of diagnostic uncertainty for 
these patients. 
Recently, a rapid assay based on the analysis of rRNA processing has been proposed to 
ascertain the presence of a ribosomopathy. Nevertheless, this approach is not suitable for 
those forms of DBA caused by genes not involved in ribosome biogenesis. 
Taking into account the lack of a specific diagnostic assay new strategies need to be 
developed to support DBA diagnosis. 
The aim of my PhD project was to improve DBA diagnosis working on two different 
approaches: the development of a new diagnostic assay based on the study of extracellular 
vesicles and the screening of two new candidate genes. 
During the three years of my PhD program I contributed to the establishment of a new 
diagnostic tool based on the immunophenotypic profiling of erythroid progenitor-derived 
4
  
 
 
extracellular vesicles (EVs) (Macrì et al., 2015). EVs are membrane bound organelles 
released by various cell types. Their membrane displays typical markers of the parental cell 
of origin. Since EVs are detectable in body fluids, they have been developed as diagnostic 
and prognostic biomarkers in several disorders. Our approach was innovative since no data 
were available on erythroid progenitor-derived EVs. We chose CD34, CD71 and CD235a 
markers to study erythroid EVs. We characterized the EVs immunophentoypic profiles of 
13 DBA patients, 22 healthy controls and 16 patients with other haematological diseases. 
Among the different EV clusters we found, only the CD34+/CD71low population showed a 
statistically significant difference between DBA patients and controls (p< 0.05). The 
absence of this cluster is in agreement with the low levels of BFU-E found in DBA patients. 
The assessment of ROC curves demonstrated the potential diagnostic value of this 
population. We suggested that this assay may be useful to improve DBA diagnosis as a 
quicker and less invasive alternative to BM BFU-E culture analysis. 
In the second part of my PhD project I looked for new DBA genes in a subset of Italian 
DBA patients who were already screened for the 7 RP genes (RPS10, RPS17, RPS19, 
RPS26, RPL5, RPL11, and RPL35A) that are most frequently mutated in DBA patients, and 
for GATA1 and resulted mutation negative. I sequenced two genes: MCM2, a gene involved 
in erythropoiesis and WBSCR22, a gene involved in ribosome biogenesis.  
The study of MCM2 was carried out in collaboration with Dr. David Bodine (National 
Human Genome Research Institute, Genetics and Molecular Biology Branch, Bethesda, 
MD) and Dr. Jason Farrar (University of Arkansas for Medical Sciences, Little Rock, AR) 
who found a MCM2 homozygous mutation in a proband from a DBA American family 
showing possible recessive inheritance. They also demonstrated the role of MCM2 in 
erythropoiesis. Moreover they found two distinct heterozygous mutations in 2 out of 40 
sporadic US patients. Thus, we selected 53 DBA patients from Italian registry and screened 
MCM2 by Sanger sequencing. The only SNV that I found was a heterozygous change in 
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exon7: c.G1186A: p.A396T. This SNV was the same variant found by our US collaborators 
in a single patient out of 40. Analysis of this change led to the consideration that this SNV 
could be considered as a VUS (Variant of Unknown Significance). Subsequent analysis of 
rRNA processing in our proband suggested the involvement of a RPL and led to the 
previous reassessment of sequencing analysis. Finally, a splicing variant in RPL5 was 
found. 
In conclusion, our results on MCM2 screening show that this gene is not mutated in our 
patients panel.  
WBSCR22 was studied because it is a key player in 40S biogenesis. Downregulation of  
WBSCR22 leads to an accumulation of pre-rRNA 18SE by Northern Blot. Thus, we 
decided to screen this gene in a single patient who showed this specific rRNA pattern but 
no sequence variation was found. 
In conclusion, we suggest that all the DBA patients with an unusual rRNA precursor pattern 
should be studied by exome or whole genome sequencing.    
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Ho svolto il mio periodo di Dottorato nel laboratorio della Prof.ssa Irma Dianzani, presso il 
Dipartimento di Scienze della Salute di Novara. Il mio progetto di tesi è stato incentrato 
sull’anemia di Diamond-Blackfan (DBA), una rara aplasia eritroide che, solitamente, 
compare nel primo anno di età e spesso è associata a malformazioni. I pazienti presentano 
un’anemia normocromica, macrocitica con reticolocitopenia. Altre importanti 
caratteristiche della DBA sono elevati livelli di emoglobina fetale e un’attività elevata 
dell’enzima eritrocitario adenosina deaminasi.  
La lesione molecolare presente nella DBA determina un blocco nel differenziamento a 
livello dei progenitori eritroidi nel midollo osseo. Infatti, sia BFU-E che CFU-E non si 
differenziano efficientemente e mostrano un fenotipo pro-apoptotico. L’analisi delle colture 
midollari derivate da pazienti con DBA mostra una riduzione dei progenitori eritroidi.  
La diagnosi risulta essere prevalentemente clinica ed è resa difficoltosa dal fatto che i 
sintomi sono comuni ad altre sindromi da insufficienza midollare.  
La DBA è la prima malattia descritta la cui causa risieda in difetti della biogenesi del 
ribosoma e del processamento dell’rRNA. Sono state descritte mutazioni in eterozigosi in 
17 geni codificanti proteine della subunità piccola (RPS) o grande (RPL) del ribosoma. 
Complessivamente il 65% dei pazienti presenta una mutazione in uno di questi geni mentre 
il rimanente 35% non ha una diagnosi molecolare. 
Le mutazioni nelle RP possono essere ereditate con un pattern autosomico dominante o 
possono essere de novo. Recentemente, sono state riscontrate rare mutazioni in GATA1 e 
TSR2, dimostrando che anche geni non codificanti proteine ribosomali possono causare la 
DBA.  
Recentemente è stato sviluppato un saggio basato sull’analisi dell’rRNA per accertare la 
presenza di una ribosomopatia. Questo approccio non è, però, idoneo per quelle forme di 
DBA causate da geni non coinvolti nella biogenesi del ribosoma. 
Tenuto conto della mancanza di uno specifico test diagnostico, è stato necessario sviluppare 
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strategie alternative per supportare la diagnosi di DBA. 
L’obiettivo del mio progetto di tesi di Dottorato è stato quello di migliorare la diagnosi di 
DBA con due approcci distinti: lo sviluppo di un nuovo saggio diagnostico basato sullo 
studio delle vescicole extracellulari e lo screening di due nuovi geni candidati. 
Durante i tre anni di Dottorato ho contribuito allo sviluppo di un nuovo test diagnostico 
basato sul profilo immunofenotipico delle vescicole extracellulari derivate dai progenitori 
eritroidi (Macrì et al., 2015). 
Le vescicole extracellulari sono degli organelli delimitati da membrana che vengono 
prodotti da diversi tipi cellulari. La loro membrana presenta marcatori tipici delle cellule da 
cui derivano. Poichè le vescicole extracellulari sono presenti in molti fluidi corporei, sono 
state sviluppate come biomarcatore diagnostico e prognostico in diverse patologie. 
Il nostro approccio è stato innovativo poichè non esistevano dati sulle vescicole 
extracellulari derivate dai progenitori eritroidi. Come marcatori per studiare vescicole 
extracellulari di origine eritroide sono stati selezionati i seguenti marcatori: CD34, CD71 e 
CD235a. E’ stato caratterizzato il profilo immunofenotipico di 13 pazienti con la DBA, 22 
controlli sani e 16 pazienti con altre malattie ematologiche. Tra le diverse popolazioni di 
EV che sono state identificate, solamente la popolazione CD34+/CD71low ha mostrato una 
differenza statisticamente significativa tra i pazienti DBA e i controlli (p< 0.05). L’assenza 
di questo cluster è coerente con il ridotto numero di BFU-E trovato nei pazienti DBA. 
La valutazione delle curve ROC ha dimostrato il potenziale valore diagnostico di questa 
popolazione di vescicole extracellualri. I nostri risultati suggeriscono che questo test possa 
essere utile per migliorare la diagnosi di DBA in quanto più veloce e meno invasivo rispetto 
all’analisi delle colture di BFU-E da midollo osseo. 
La seconda parte del mio progetto di tesi è stata focalizzata sulla ricerca di nuovi geni DBA 
in un gruppo di pazienti italiani che erano già stati sequenziati per i 7 geni RP più 
frequentemente mutati  (RPS10, RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A) e per 
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GATA1 e in cui non erano state riscontrate mutazioni. Ho sequenziato due geni: MCM2, un 
gene coinvolto nell’eritropoiesi e WBSCR22, un gene coinvolto nella biogenesi del 
ribosoma.  
Lo studio di MCM2 è stato condotto in collaborazione con il Dr. David Bodine (National 
Human Genome Research Institute, Genetics and Molecular Biology Branch, Bethesda, 
MD) e con il Dr. Jason Farrar (University of Arkansas for Medical Sciences, Little Rock, 
AR) i quali hanno identificato una mutazione omozigote in MCM2 in un probando di una 
famiglia americana con una possibile ereditarietà autosomica recessiva. È stato 
successivamente dimostrato il ruolo di MCM2 nell’eritropoiesi. Inoltre, sono state 
identificate due distinte mutazioni in eterozigosi in 2 su 40 pazienti americani sporadici. 
Di conseguenza sono stati selezionati 53 pazienti DBA dal registro italiano e MCM2 è stato 
sequenziato con metodo Sanger. L’unica variazione a singolo nucleotide (SNV) che è stata 
riscontrata, è un cambiamento in eterozigosi nell’esone 7: c.G1186A: p.A396T. Questa 
SNV è stata identificata anche dai nostri collaboratori in un paziente americano su 40. 
L’analisi di questa variante ha portato alla considerazione che si tratti di una variante con un 
significato non noto. Successive analisi del processamento dell’rRNA nel nostro probando 
hanno suggerito il coinvolgimento di una RPL. Ciò ha portato alla rivalutazione della 
precedente analisi di sequenziamento che ha permesso di identificare una variante di 
splicing in RPL5. 
In conclusione, i nostri risultati sullo screening di MCM2 hanno mostrato che questo gene 
non è mutato nel nostro pannello di pazienti.  
WBSCR22 è stato studiato poichè ricopre un ruolo importante nella biogenesi della subunità 
40S del ribosoma. La  downregolazione di  WBSCR22 porta ad un accumulo del pre-rRNA 
18SE visualizza mediante analisi di Northern Blot, E’ stato quindi analizzato un paziente 
che mostrava questo specifico pattern degli rRNA, ma nessuna variazione della sequenza è 
stata osservata. 
10
  
 
 
In conclusione, suggeriamo che tutti pazienti con la DBA con un pattern dei pre-rRNA 
inusuale debbano essere sottoposti al sequenziamento dell’esoma o dell’intero genoma. 
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Erythropoiesis  
 
Human blood contains approximately 5×106 erythrocytes per microliter (normal range 
4.7×106/µl to 6.1×106/µl for males and 4.2×106/µl to 5.4×106/µl for females). These cells 
have an average life span of 120 days. New erythrocytes are constantly produced in the 
bone marrow (BM), which provides a niche consisting of endothelial cells of the vascular 
system, osteoblasts, stromal cells, hematopoietic cells, and the extracellular matrix. 
Production of erythrocytes at high scale requires an intricate coordination between intrinsic 
and extrinsic erythroid programmes.  
Erythropoiesis is the process through which red blood cells (RBCs) are produced from 
haematopoietic stem cells (HSC). It is a tightly regulated process that can be divided into 
two stages: early and late (Figure 1). During the early stage of erythropoiesis, HSCs 
sequentially give rise to common myeloid progenitor, megakaryocyte-erythrocyte 
progenitor, burst-forming unit-erythroid (BFU-E), and colony-forming unit-erythroid 
(CFU-E) cells (Hattangadi et al. 2011). BFU-E and CFU-E cells have been traditionally 
defined by colony assays (DeZern et al. 2013). BFU-E have large colonies containing up to 
several thousand hemoglobinized cells that appear after 10–14 days in semi-solid culture. 
Their growth is dependent on several factors, such as stem cell factor (SCF), 
thrombopoietin (TPO), interleukin 3 (IL-3), IL-11, and FLT3-ligand. More mature 
erythroid progenitors, CFU-E, consist of small colonies of 16–125 cells that appear after 5–
8 days in semi-solid culture (Liang and Ghaffari 2016). While not required for producing 
BFU-E and CFU-E cells from stem cells per se, EPO is essential for RBC production from 
CFU-E and acts as a strong stimulator by inducing CFU-E survival and proliferation (Wu et 
al. 1995; Gautier et al. 2016). 
It is well known that CD34 and CD45 markers are expressed in human hematopoietic 
progenitor cells. Moreover, CD36 and CD71 markers are known to be earlier erythroid 
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markers than glycophorin A (CD235a). Recently, an exhaustive study performed by Li et 
al., demonstrated that BFU-E and CFU-E are characterized by CD45+CD235a-IL-3R-
CD34+CD36-CD71low and CD45
+CD235a-IL-3R-CD34-CD36+CD71high phenotypes, 
respectively (Li et al. 2014).  
During the late stage (also named as terminal erythroid differentiation), morphologically 
recognizable pro-erythroblasts undergo mitosis to produce basophilic, polychromatic, and 
orthochromatic erythroblasts. The pro-erythroblast, the first identifiable precursor, is the 
most voluminous and has a large nucleus. The basophilic erythroblast is a cell with a large 
diameter in which the chromatin is condensed and the cytoplasm is intensely basophilic 
because of the abundance of free ribosomes. The polychromatic erythroblast is 
characterized by the disappearance of the nucleolus and the synthesis of hemoglobin whose 
accumulation increases acidophilia. Finally, the ortochromatic erythroblast has a small 
nucleus with very condensed chromatin and  acidophilus cytoplasm.  
The erythroid precursor maturation is characterized by a reduction in the cell volume and 
mitotic activity which stops at the level of ortochromatic erythroblast. Immunophenotypic 
profiling of erythroid precursors allowed to identify and isolate  terminally differentiating 
erythroblasts at distinct developmental stages (Hu et al. 2013; Fajtova et al. 2013). 
The enucleation by the last precursor leads to the reticulocyte (R1) that goes through the 
wall of the sinusoids into the bloodstream. The differentiation of reticulocyte (R2) in the 
mature erythrocyte is characterized by degradation of cytoplasmic organelles and the 
further reduction of the cell volume that is accompanied by a rearrangement of the plasma 
membrane through vesiculation (Griffiths et al. 2012). Reticulocytes represent 
approximately 0.8% of all circulating erythrocytes and their number is an index of the BM 
function (Buttarello 2016). 
In conclusion, erythroid cells at the terminal stages of differentiation have lost their 
nucleus, endoplasmic reticulum, and mitochondria, and are full of hemoglobin. 
14
  
 
 
 
 
 
 
Figure 1. General scheme of erythropoiesis (Sinclair 2013). 
 
Diamond-Blackfan Anemia  and other IBMFS 
 
Inherited bone marrow failure syndromes (IBMFS) are a heterogeneous group of rare 
hematological disorders characterized by the impairment of hematopoiesis and are  
characterized by specific clinical presentation and pathogenic mechanism. IBMFS include 
Fanconi Anemia (FA), Dyskeratosis Congenita (DC), Diamond Blackfan Anemia (DBA) 
and Shwachman-Diamond syndrome (SDS) (Collins and Dokal 2015). 
The basic defect in Fanconi Anemia involves one of multiple components of the nuclear 
protein complex that recognizes, excises and repairs inter-strand DNA crosslinks that arise 
from the activity of reactive oxygen species and other endogenous DNA cross-linkers as 
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well as toxic exogenous DNA crosslinking agents (Brosh et al. 2017).  
Dyskeratosis Congenita is a syndrome that results in bone marrow failure with macrocytic 
anemia due to inability to maintain the chromosome telomeres (Perdigones et al. 2016). 
Fanconi Anemia and Dyskeratosis Congenita affect multiple hematopoietic lineages, 
whereas the erythroid lineage at the BFU-E and CFU-E stages are specifically affected in 
Diamond–Blackfan Anemia. Lastly, also Schwachmann-Diamond syndrome may show 
macrocytic anemia together with pancreas insufficiency (Roach et al. 2015). 
These inherited anemias are mainly diagnosed in infancy and are often associated with 
malformations (Koury 2014).  
The presence of normochromic anemia with severe reticulocytopenia and marked reduction 
or absence of erythroid progenitors from the BM is defined as pure red cell aplasia (PRCA). 
There are two main clinical entities of PRCA in paediatric patients: DBA and transient 
erythroblastopenia of childhood (TEC). TEC is idiopathic and self-limiting and occurs in 
previously haematologically normal children, whereas DBA is an inherited disorder (van 
den Akker et al. 2014). 
 
DBA clinical features and diagnosis 
 
Diamond-Blackfan Anemia (DBA, OMIM 105650), was first reported by Josephs in 1936 
and redefined as a distinct clinical entity by Diamond and Blackfan in 1938 (Lipton and 
Ellis 2009). DBA is usually diagnosed during the first months after birth and has an 
incidence of 6-7 newborns per million live births (Vlachos et al. 2008). 
The primary hematological feature of DBA is a normochromic and  macrocytic anemia with 
normal leukocytes and platelets and the presence of reticulocytopenia (Vlachos et al. 2008). 
Elevated fetal haemoglobin levels (HbF) and elevated erythrocyte adenosine deaminase 
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(eADA) activity are other features of DBA (Alter et al. 2013; Narla et al. 2016) (Table 1).  
DBA needs to be distinguished by other IBMFS which can have overlapping clinical 
presentations (Dianzani and Loreni 2008). FA is excluded by negative results in a 
chromosome breakage assay, while the absence of telomere shortening rules out DC. SDS 
is characterized by pancreatic insufficiency and is often associated with skeletal 
malformations and neutropenia. Distinguishing between DBA and TEC, especially in the 
first year of life, can be challenging (van den Akker et al. 2014). 
The absence of unique clinical features often makes DBA a diagnosis of exclusion. 
 
Diagnostic criteria 
Age less than 1 year 
Macrocytic anemia with no other significant cytopenias 
Reticulocytopenia 
Normal marrow cellularity with a paucity of erythroid precursors 
Supporting criteria 
Major 
Identification of a pathogenic variant in one of the genes known 
to be associated with DBA 
Family history of DBA consistent with autosomal dominant 
inheritance 
Minor 
Elevated erythrocyte adenosine deaminase activity (eADA) 
Congenital anomalies described in ‘‘classical’’ DBA 
Elevated HbF concentration 
No evidence of another IBMFS 
One or more congenital anomalies described in classic DBA 
 
Table 1. Diagnosing Diamond-Blackfan anemia (Vlachos et al. 2008; Clinton and Gazda 2016). 
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Features of non-classic DBA 
Mild or absent anemia with only subtle indications of erythroid 
abnormalities such as macrocytosis, elevated eADA, and/or 
elevated HbF concentration 
Onset later in life 
Congenital anomalies or short stature consistent with DBA and 
minimal or no evidence of abnormal erythropoiesis 
 
Table 2. Features of non-classic DBA (Clinton and Gazda 2016). 
 
Fifty per cent of DBA patients show congenital abnormalities such as craniofacial, thumb, 
kidney and heart malformations, whereas 30% of patients show growth retardation 
(Vlachos and Muir 2010; Lipton et al. 2006). The phenotypic spectrum of DBA is broad. 
DBA shows autosomal dominant transmission. Penetrance is incomplete and expressivity 
widely variable even in patients from the same family. A non-classic form includes mild 
anemia or no anemia with only subtle erythroid abnormalities, or physical malformations 
without anemia. In non-classic DBA, anemia develops later than one year of age (Vlachos 
et al. 2008) (Table 2). 
DBA is a cancer predisposition syndrome with a preponderance of hematological 
malignancies, but also solid tumors such as osteogenic sarcoma may occur. The cumulative 
incidence of malignancy is approximately 40% by age 46 years (Vlachos et al. 2012).  
Approximately 20% of patients show a spontaneous improvement of anemia resulting in 
independence of therapy for at least 6 months with acceptable hemoglobin levels (Clinton 
and Gazda 2016). The mechanism behind remission remains unknown and about 15% of 
those who enter remission relapse (Dianzani and Loreni 2008). 
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Genetics  
 
DBA is considered as the prototype of ribosomopathies. The first DBA gene identified was 
RPS19 (MIM# 603474), that is mutated in ~27% of cases. To date, mutations in other 16 
ribosomal protein (RP) genes either of the small (RPS7 MIM# 612563, RPS10 MIM# 
603632, RPS15A MIM# 603674, RPS17 MIM# 180472, RPS24 MIM# 602412, RPS26 
MIM# 603701, RPS27 MIM#603702, RPS28 MIM#603685, RPS29 MIM#603633) or 
the large (RPL5 MIM# 612561, RPL11 MIM# 612562, RPL15 MIM #604174, RPL26 MIM 
#603704, RPL27 MIM #607626, RPL31, RPL35A MIM# 180468) subunit have been 
detected. In total, 65% of patients carry a mutation in one of these17 genes (Danilova and 
Gazda 2015). 
Ribosomal gene mutations may be inherited with an autosomal dominant pattern or may 
arise de novo. Most DBA genetic lesions lead to loss of function (LOF), but a dominant 
negative mechanism was proposed to explain the effect of a missense mutation (RPS19; 
R62W) (Devlin et al. 2010). 
Approximately 35% of patients with a clinical diagnosis of DBA do not have an identifiable 
RP gene abnormality (Danilova and Gazda 2015; Gerrard et al. 2013). 
More than 200 extra-ribosomal factors are required to synthesize ribosomes and may be 
involved in DBA pathogenesis. In this regard, TSR2 which encodes a direct binding partner 
of RPS26, has been proposed as a new DBA gene. This supports the involvement of non-RP 
genes in the disease (Gripp et al. 2014). Mutations in the X-linked transcription factor 
GATA1, which is essential for erythropoiesis, have been described in a small number of 
DBA patients (Sankaran et al. 2012; Parrella et al. 2014). 
These findings not only increase the growing repertoire of DBA genes, but potentially 
challenge the current view that failure to adequately synthesize ribosomes leads, per se, to 
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the erythroid and possibly the non-hematologic manifestations of DBA (Farrar 2014) . 
 
 Ribosome Biogenesis and rRNA processing  
 
 
 
Figure 2. Scheme of rRNA processing (Ellis and Massey 2006). 
 
Ribosome biogenesis involves over 200 different factors, around 80 ribosomal proteins and 
more than 100 small nucleolar (sno)RNAs. 
Mammalian cells have hundreds of copies of tandemly repeated ribosomal DNA (rDNA) 
that are simultaneously transcribed to pre-ribosomal RNA (pre-rRNA) in the nucleolus. The 
47S pre-rRNA is transcribed by RNA polymerase I and processed to mature 28S, 18S and 
5.8S rRNA. The 5S rDNA is transcribed by RNA polymerase III in the nucleus. Pre-rRNA 
processing is driven by endonucleases and exonucleases that remove ITS and ETS, 
respectively (Figure 2). During these steps, the pre-47S rRNA is associated with ribosomal 
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proteins, ribonuclease, RNA helicases and other extra-ribosomal factors, to form the pre-
90S ribosome. Then, the pre-90S ribosome evolves into pre-40S containing the pre-21S 
rRNA, and pre-60S containing the pre-32S rRNA. The pre-rRNA 21S matures in 18SE 
rRNA and then in 18S, and pre-rRNA 32S matures in 28S and 5.8S rRNA (Figure 2). The 
two ribosomal subunits are then independently exported to the cytoplasm, where the 40S 
subunit interacts with the mRNA, joins with the 60S and perform protein synthesis (Henras 
et al. 2015). 
Haploinsufficiency or reduced expression of a ribosomal protein results in the defective 
processing of the ribosomal RNA precursors and in decreased levels of the corresponding 
ribosomal subunit.  
The RPS19 protein was demonstrated to play an important role in 18S rRNA maturation in 
yeast and in human cells (Leger-Silvestre et al. 2005; Choesmel et al. 2007; Flygare et al. 
2007; Idol et al. 2007). In particular, haploinsufficiency of RPS19 leads to an accumulation 
of pre-rRNA 21S, a reduction of 40S subunits and an increase of free 60S subunits (Flygare 
et al. 2007).  
Alterations of pre-RNA processing and small or large ribosomal subunit synthesis were 
demonstrated in human cells with RPS24, RPS7, RPL35A, RPL5, RPL11, and RPL26 
deficiency, respectively (Choesmel et al. 2008; Farrar et al. 2008; Gazda et al. 2008; Gazda 
et al. 2012). Finally, mutations in RPL5 and RPL11 cause an accumulation of pre-rRNA 
32S which is visible even in ethidium bromide gel staining and capillary electrophoresis 
(Figure 3) (Farrar et al. 2014).  
The role of each RP is crucial in different steps of rRNA processing and can be evaluated 
using Northern Blot with specific probes for each pre-rRNAs (Flygare et al. 2007; Farrar et 
al. 2008; Farrar et al. 2011) (Figure 3).  
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Figure 3. Northern blot analysis of pre-rRNA processing. Total RNA was extracted from activated 
lymphocytes, resolved by electrophoresis and visualized by ethidium bromide staining. Northern 
blot with a probe specific for 32S pre-rRNA was performed to validate the result obtained by gel 
staining. 
 
A rapid and convenient assay based on capillary electrophoresis was proposed to support 
DBA diagnosis (Quarello et al. 2016). 28S and 18S rRNAs represent the major peaks 
resolved by capillary electrophoresis (Figure 4). It was reported that the ratio of 28S/18S is 
higher in patients with RPS mutations whereas it is lower in patients with RPL mutations 
(Quarello et al. 2016). In addition, a prominent peak corresponding to pre-rRNA 32S was 
visible in patients with RPL deficiency (Figure 4). Thus, analysis of rRNAs 28S/18S and 
32S/28S ratios by capillary electrophoresis, was proposed to address the molecular 
screening in the first step of DBA diagnosis (Quarello et al. 2016) (Figure 4). 
This approach would only be supportive by exclusion for DBA caused by defects in non-
ribosomal protein genes. 
Finally, the depletion of RPS19 causes a reduction of rRNA synthesis in cell lines of both 
erythroid and non-erythroid origin (Juli et al. 2016).  
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Figure 4. Agilent Bioanalyzer 2100 electropherograms obtained from total RNA of peripheral 
blood mononuclear cells of DBA patients carrying RPS and RPL gene mutations and a healthy 
control (Quarello et al. 2016). 
 
DBA models 
 
To reproduce the pathological conditions and understand the pathogenetic mechanism 
underlying the disease, different DBA models were developed. 
The first attempt to obtain a murine model by knock-out of RPS19 failed as the 
homozygous embryo did not survive the first stages of development. However, although the 
homozygous loss of RPS19 was lethal before implantation, the mouse carrying an 
heterozygous deletion, exhibited no pathological phenotype (Matsson et al. 2004). This was 
probably due to the onset of compensatory mechanisms (Ellis and Lipton 2008). 
Another mouse model carrying an heterozygous RPS19 missense mutation (Y54N) 
similarly showed only mild anemia. Even in this case, the homozygous mutation was lethal 
(McGowan et al. 2008). Furthermore, a transgenic mouse model with an RPS19 missense 
mutation (R62W) showed retarded growth and mild anemia together with reduced numbers 
of erythroid progenitors (Devlin et al. 2010). 
The first mouse model that recapitulated the disease was obtained using transgenic RNA 
interference that allowed an inducible downregulation of RPS19. This mouse developed 
macrocytic anemia, leukocytopenia and variable platelet count (Jaako et al. 2011). 
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Several zebrafish DBA model were generated using the technique of "Morpholino" for 
RPS19 (Danilova, Sakamoto, and Lin 2008; Uechi et al. 2008), RPL11 (Danilova, 
Sakamoto, and Lin 2011), RPS29 (Taylor et al. 2012), RPS24 (Song et al. 2014), RPS27 
(Wang, Yoshida, et al. 2015), RPL27 (Wang, Yoshida, et al. 2015) and RPL5 (Wan et al. 
2016).  
In order to reproduce the condition of protein haploinsufficiency, different cell culture 
models, characterized by silencing of a RP by RNA interference, were developed. Knock-
down of RPS19 using a tetO system in TF1 erythroid leukemia cells caused reduced 
proliferative ability and cell differentiation (Miyake et al. 2005; Miyake et al. 2008). In TF1 
cells other RP were silenced, including RPL5 and RPL11 (Aspesi et al. 2014; Moniz et al. 
2012).  
Finally, downregulation of RPS19 in human CD34+ cells induced decreased proliferation 
and differentiation of erythoid progenitors cells and cell cycle arrest (Ebert et al. 2005; 
Flygare et al. 2005; Kuramitsu et al. 2008). 
 
 Pathogenetic mechanisms  
 
Ribosome synthesis is cell cycle controlled: it is sensitive to growth factors and nutrient 
signalling and inhibited upon stress signals. Haploinsufficiency of a RP can cause 
ribosomal stress leading to a pro-apoptotic phenotype of erythroid progenitors.  
One of the first indications that p53 is involved in ribosome stress was the finding that a 
mutation in Bop1, which is involved in maturation of rRNAs, leads to p53-dependent cell 
cycle arrest in mouse cells (Pestov, Strezoska, and Lau 2001). Moreover, RPS6 
haploinsufficiency activates p53 in mouse embryos and T cells (Panic et al. 2006). 
Studies in zebrafish and mouse established p53 activation as a general response to RP 
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haploinsufficiency (Dutt et al. 2011; Taylor et al. 2012; McGowan et al. 2008). Several 
hypotheses were suggested to explain the activation of p53 in DBA. The nucleolus was 
proposed to be a universal stress sensor that is responsible for the maintenance of a low 
level of p53 in the cell. However, RP deficiency does not always lead to nucleolar 
disruption, suggesting that other mechanisms sense ribosomal stress as well (Fumagalli et 
al. 2009). Moreover, some RPs were shown to bind MDM2 and to inhibit its binding to 
p53, leading to p53 stabilization and cell cycle arrest (Danilova and Gazda 2015) (Figure 
5). Decreased RP synthesis activates p53, inducing downstream events that result in cell 
cycle arrest or apoptosis (Figure 5). 
Another way of p53 activation in RP-deficient cells might be the altered nucleotide 
metabolism (Figure 5). 
 
 
 
Figure 5. Defects in ribosomal biogenesis activate p53 and other stress-response 
mechanisms (Danilova and Gazda 2015). 
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p53 might also be activated by increased levels of ROS (Reactive Oxygen Species) in RP-
deficient cells (Heijnen et al. 2014) (Figure 5). Finally, the different hypotheses of p53 
activation are not mutually exclusive.  
Conversely p53-independent pathways may contribute to apoptosis of erythroid progenitors 
(Singh et al. 2014). Studies of transcriptional responses to RP deficiency performed in p53-
negative human cell lines revealed changes in the expression of genes involved in 
metabolism, proliferation, apoptosis and cell redox homeostasis (Aspesi et al. 2014).  
Different hypotheses were proposed to explain how a defect in ribosome biogenesis 
specifically affects only erythropoiesis. The tissue-specific expression of RPs could make 
the haploinsufficiency of certain RPs as limiting factor in a specific tissue (Ellis and 
Massey 2006). Erythroid committed cells may be more sensitive to p53 activation as 
compared to other hemopoietic lineages (Dutt et al. 2011).  
Furthermore, several RPs are known to have extra-ribosomal functions. It is speculated that 
their mutations cause the loss of hypothetical functions, that are specific for erythroid 
maturation, possibly in combination with ribosomal stress (Lipton and Ellis 2009). 
The reduction in ribosomes causes a defect in general protein synthesis, emphasized in a 
rapidly proliferating tissue. In addition, erythroblast cells undergo chromatin condensation 
and enucleation, and it is likely that a great number of ribosomes must be generated in a 
very short time, to allow the synthesis of globins, also when cells will be less efficient to 
make new ribosomes (Lipton and Ellis 2009). 
It was also demonstrated that the alteration of heme metabolism could play a role in the 
pathogenesis of DBA. The insufficient production of hemoglobin and the accumulation of 
the excess of heme might contribute to oxidative stress in erythroid progenitors (Ellis 
2014). The heme overload could also contribute to defective erythropoiesis in DBA by 
affecting the proliferation, apoptosis, and differentiation of early erythroid progenitors 
(Mercurio et al. 2016; Yang et al. 2016).  
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Finally, the reduced expression of GATA1 by DBA cell models provides a possible link 
between ribosome defect and erythropoiesis failure (Ludwig et al. 2014).  
 
Standard treatment 
 
DBA patients are first treated with steroids that may carry many side effects (Sjogren et al. 
2015). The subset of DBA patients who do not respond to corticosteroids or require high 
doses of steroids with unacceptable toxicities receives chronic red cell transfusions. 
Transfusional iron overload is a major cause of morbidity and mortality in DBA and iron 
chelation is needed to avoid secondary hemochromatosis (Roggero et al. 2009).  
The only curative option for hematological manifestations of DBA is allogenic 
hematopoietic stem cell transplantation (HSCT). The avoidance of iron overload due to 
regular transfusions is the main reason to consider HSCT from either related or HLA-
compatible unrelated donors in DBA children (Fagioli et al. 2014).  
In the absence of HLA compatible donors, haploidentical parents may be considered as 
donors, although a more intensive conditioning regimen is required and patients show a 
high risk of both acute and chronic graft-versus-host disease (GvHD). Moreover, the risk of 
using silent carriers as donors should be considered. 
Taking into account all these issues, the assessment of alternative therapies is needed in 
order to develop a definitive cure for DBA. 
 
New drugs 
 
Recently, important advances have been made in the assessment of small molecules as 
potential drugs to treat DBA. The BM failure is due to BFU-E erythroid progenitors that 
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undergo apoptosis. As BFU-E are not sensitive to EPO, the attempt to use this cytokine in 
DBA failed (Flygare et al. 2011). Otherwise CFU-E, that express EPO receptor, are too few 
in number to sustain erythropoiesis. Therefore, another approach is the development of 
drugs that selectively target BFU-E.  
It was demonstrated that glucocorticoids increased red blood cell production stimulating 
BFU-E self- renewal (Flygare et al. 2011). A crucial gene that is upregulated by 
glucocorticoids is PPAR-α (Lee et al. 2015). The use of PPAR-α agonists such as 
fenofibrate was shown to synergize with glucocorticoids, promote BFU-E self- renewal and 
improve erythropoiesis. This effect might reduce the dose of glucocorticoids and their many 
adverse effects. Interestingly, fenofibrate is already approved by FDA to treat 
hypercholesterolemia and hypertriglyceridemia. Discussions are currently underway to set 
up a clinical trial to test this drug in DBA patients.   
The important discovery of TGF-β pathway involvement in DBA lead the way to new 
drugable targets (Ge et al. 2015). Importantly, blocking of TGF-β signaling by receptor 
kinase inhibition, enhanced BFU-E self-renewal and total erythropoiesis in a 
glucocorticoid-independent manner. Thus, TGF- β inhibitors like Galunisertib (LY2157299 
H2O, Lilly Oncology), might be used, as alternative to steroids to treat EPO-unresponsive 
anemias such as DBA. Whether this small molecule is a suitable candidate for the treatment 
of DBA patients remains to be determined (Gao et al. 2016). 
Finally, in 2011 a group of DBA patients have been enrolled for a clinical trial 
(NCT01464164) to test the efficacy of Sotatercept (ACE-011, Celgene). 
This drug is an activin receptor type IIA ligand trap and inhibits signaling downstream of 
TGF-β superfamily members. Previous clinical trials for other clinical conditions reported 
that women treated with this drug produced increased numbers of erythrocytes and 
hemoglobin level (Sherman et al. 2013). Moreover, anemia has been ameliorated in murine 
models after administration of RAP-011 (murine orthologous of ACE-011) (Carrancio et al. 
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2014). RAP-011 improved erythropoiesis in DBA zebrafish model further supporting the 
use of Sotatercept in patients (Ear et al. 2015). 
All of these drugs were already employed in humans for other clinical needs and this means 
that their adverse effects are well known. However, detailed studies have to be carried out 
to evaluate the efficacy of these small molecules as innovative therapeutic options for DBA 
patients. 
 
Gene therapy  
 
Important results have been reported in gene therapy of HSC to treat hematological and 
neurodegenerative storage disorders (Naldini 2015). It is well known that HSC have a great 
therapeutic potential due to their self-renewal ability. Thus, this population represents an 
ideal target for stable genomic integration of therapeutic genes and also a valid alternative 
to HSCT especially when no matched donor is available. Recent progress has been reached 
in gene therapy of hemoglobinopathies such as Beta-Thalassemia and Sickle Cell Disease 
(Cavazzana-Calvo et al. 2010; Cavazzana et al. 2015). Finally, in 2012 the beginning of 
Phase I/II Gene Therapy Trial of Fanconi Anemia Patients with lentiviral vectors (LV) 
carrying the FANCA gene was reported. This result supports the translation from bench to 
the clinic of gene therapy in BM failure syndromes ('Phase I/II Gene Therapy Trial of 
Fanconi Anemia Patients with a New Orphan Drug Consisting of a Lentiviral Vector 
Carrying the FANCA Gene: A Coordinated International Action (EuroFancolen)'  2015).  
Gene therapy in DBA may avoid a lot of critical aspects of allogenic HSCT such as 
intensive post transplant immunosuppressive treatment to prevent GvHD, a condition that 
results in a poor patients quality of life. Autologous cells that have been corrected by ex 
vivo transduction should display a selective proliferative advantage in BM repopulation and 
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this may reduce the preconditioning regimen dose and its side effects. 
In the past different investigators tried to assess the feasibility of gene therapy in DBA. In 
particular Hamaguchi et al. reported that transduction of RPS19 cDNA using oncoretroviral 
or LV vectors into RPS19-deficient CD34+ cells from DBA patients improves erythroid 
colonies formation both in solid and liquid cultures (Hamaguchi et al. 2002; Hamaguchi et 
al. 2003). Moreover, Flygare et al. showed that high levels of RPS19 are required to 
increase erythroid differentiation in RPS19-deficient DBA CD34+ cells in vitro. Corrected 
DBA patient cells displayed a proliferative advantage in vivo and consequently an improved 
engraftment (Flygare et al. 2008). 
The use of animal models that recapitulate DBA is imperative to investigate the feasibility, 
the therapeutic efficacy and the safety of gene therapy. The mouse model produced by 
Jaako et al., developed macrocytic anemia and BM failure that were restored in vitro by 
RPS19 gene transfer using LV (Jaako et al. 2011). Moreover, transplant of corrected 
RPS19-deficient cells in recipient mice cured the anemia and the lethal BM failure without 
signs of vector-mediated toxicity (Jaako et al. 2014).  
To minimize the issues concerning ex vivo gene delivery, the in situ gene transfer in BM 
was proposed. In particular, a Fanconi Anemia animal model has been treated with 
intraosseous infusion of LV encoding FANCC gene, resulting in phenotypic correction 
(Habi et al. 2010). It has been reported that intraosseous delivery of LV targeting Factor 
VIII in megakaryocytes becoming platelets corrects murine Hemophilia A (Wang, Shin, et 
al. 2015). This method should be evaluated in DBA mouse models to provide a more 
targeted approach. 
 
The breakthrough of reprogramming mature adults cells to pluripotency represents a 
revolution towards personalized therapy because the risk of immune rejection and the 
ethical concerns of using embryonic cells are eluded. Induced Pluripotent Stem Cells 
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(iPSCs), as an unlimited source of  cells, are easier than HSC to be genetically manipulated 
and entirely characterized before transplant. Garcon et al., for the first time, obtained iPSCs 
from DBA patients fibroblasts carrying mutation in RPL5 or RPS19 and provided a 
renewable reservoir of cells that display DBA pathological features (Garcon et al. 2013). 
The same investigators performed transcriptome analysis in these cells and demonstrated 
the striking dysregulation of TGF-β pathway (Ge et al. 2015). The authors also proved that 
providing a wild-type copy of the RP gene that was haploinsufficient results in the 
phenotype rescue. DBA iPSCs were corrected via complementary DNA transfer into the 
safe harbor AAVS1. It is well known that integrated trans-genes are stably expressed using 
this locus without epigenetic silencing and avoiding the insertional mutagenesis issues. This 
work represented the proof of concept that DBA iPSCs recapitulate the disease and that 
they are amenable to genetic correction. 
The clinical application of iPSCs obtained from DBA patients and genetically restored to 
regenerate the defective tissue is attractive. Nevertheless, the efficiency of DBA fibroblasts 
reprogramming to iPSCs is very low and this limits the efficacy and future use of this 
strategy. Moreover, it has to be considered that fibroblasts may show an intrinsic genetic 
instability due to the UV exposition, hampering the clinical translation of these 
reprogrammed cells (Martincorena et al. 2015). 
More in general, ten years after Yamanaka’s discovery (Takahashi and Yamanaka 2006), 
iPSCs therapies have been proved challenging to develop. However, iPSCs have made their 
mark in human disease modeling. 
Taking into account these considerations, today DBA iPSCs represent an essential tool to 
investigate the molecular mechanisms involved in this disorder although restricted to 
patient mutations. Along with editing technologies these cells may be useful to study the 
effect of a single mutation and to translate the consequent findings to a personalized 
medicine (Maeder and Gersbach 2016). 
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3. Aim 
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Because of the difficulty of establishing the diagnosis of DBA, in some instances the 
diagnosis may only be performed after other disorders have been ruled out. Further 
confounding a diagnosis of DBA is the increased identification of patients with non-
classical forms of DBA including patients with malformations without anemia or with 
anemia presenting as an adult. Molecular testing for identification of a heterozygous 
pathogenic variant in one of the known DBA genes confirm the diagnosis if clinical 
features are inconclusive (Danilova and Gazda 2015).  
The recent assay based on the analysis of pre-rRNA processing is useful to confirm the 
status of ribosomopathy and to address the sequencing screening to the large or small 
ribosomal subunit. Nevertheless, this approach is not suitable for those forms of DBA 
caused by defects in non-RP genes. 
The genes affected in approximately 35% of suspected DBA patients remain unknown 
leaving a degree of diagnostic uncertainty for these patients. The study focused on the 
screening of all 80 ribosomal proteins in a subset of DBA patients did not identify new RP 
genes (Gerrard et al. 2013). Furthermore, the paradigm of DBA as ribosomopathy was 
undermined by the discovery of non-RP genes like GATA1 and TSR2. 
Taking into account the lack of a specific diagnostic assay and the need of genetic 
confirmation in a percentage of patients, new strategies need to be developed to support 
DBA diagnosis. 
 
The aim of my PhD project was to improve DBA diagnosis working on two different 
approaches: the development of a new diagnostic assay based on the study of extracellular 
vesicles and the screening of two new candidate DBA genes. 
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4. Immunophenotypic profiling of 
erythroid progenitor-derived extracellular 
vesicles in DBA 
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Aim 
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As an alternative strategy for developing a more inclusive assay for possible use in DBA 
diagnosis I turned to the study of extracellular vesicles (EVs) whose presence may be 
altered as a consequence of increased apoptosis associated with BM failure. 
In this part of my PhD project I focused on the immunophenotypic characterization of 
erythroid EVs in ribosomal stress condition. This study was carried out in collaboration 
with the Chemical Clinical Analysis laboratory, SCDU, Azienda Universitaria Ospedaliera 
Maggiore della Carità, Novara. The aim of my study was to establish the method in our 
DBA cell model and then to analyse plasma EV of three different groups of individuals: 
DBA patients, patients with other hematological diseases, and healthy controls. We 
reasoned that erythroid EVs may vary both in vitro cell model and in the peripheral blood 
of DBA patients as a consequence of the increased apoptosis caused by ribosomal stress.  
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Rationale of the project 
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Extracellular vesicles 
 
Extracellular vescicles (EVs) are membrane-bound organelles produced by various cell 
types. Cells release EVs either constitutively or in a regulated manner and these vesicles 
harbor a specific subset of proteins, mRNAs, miRNAs, lipids and metabolites reflecting 
their parental cells and conditions.  
The exponential findings in this field demonstrated that EVs have specialized functions and 
play a key role in cell biology. In particular, EV-mediated intercellular communication has 
been reported as an evolutionarily conserved phenomenon (Deatherage and Cookson 2012). 
EVs can be detected in body fluids including blood, plasma, urine, saliva, amniotic fluid, 
milk, pleura ascites (Mathias et al. 2009; Lasser et al. 2011). For this reason, the first 
clinical application was the assessment of EVs as biomarkers for non-invasive diagnosis 
and prognosis of various human diseases (Chaput, Taieb, Schartz, et al. 2005; Choi et al. 
2013; D'Souza-Schorey and Clancy 2012; Mullier et al. 2014; Sarlon-Bartoli et al. 2013; 
Shedden et al. 2003). Different therapeutic approaches were pursued to utilize EVs and 
their mimetics for vaccine, chemotherapeutic drug and siRNA delivery (Alvarez-Erviti et 
al. 2011; Chaput, Taieb, Andre, et al. 2005; Jang et al. 2013; Kordelas et al. 2014; Lai, 
Chen, and Lim 2011).  
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Figure 6. Schematic representation of EVs (Gyorgy et al. 2011). 
 
 
The explosion of scientific data has justified the need of databases that tried to categorize 
EVs on the base of different parameters such as size, production and content. Although 
advances in this fast growing field were made, the nomenclature of EVs is still 
controversial. The most important position statement has been achieved by The 
International Society for Extracellular Vesicles with the creation of EVpedia 
(http://evpedia.info) in 2013 (Kim et al. 2013; Kim et al. 2015). Nevertheless, to date more 
than twenty different classifications converge to the term EVs.  
The most important three main categories in which EVs can be broadly divided are 
exosome, microvesicles and apoptotic bodies.  
The term exosome (EXO) comprises preformed vesicles which are smaller than 100nm 
with a density between 1.13 and 1.19 g/ml. EXO originate from intracellular multivesicular 
bodies (MVB). They are released via exocytosis, when MVB leave the lysosomal pathway 
and fuse with the plasma membrane (Gyorgy et al. 2011).  
EXO were mainly characterized in immunity and cancer. They are involved in antigen 
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presentation, immunostimulation, tumour growth, metastasis and angiogenesis (Thery, 
Ostrowski, and Segura 2009; Weidle et al. 2017; van der Pol et al. 2012). They can protect 
tumour cells inhibiting antitumor drug accumulation and contribute to multidrug resistance 
(Ciravolo et al. 2012).  
Microvesicles (MV) are surrounded by phospholipid bilayer and have a diameter of 50-
1000nm. They have not an endosomal origin and are directly shed from budding of plasma 
membrane (Gyorgy et al. 2011). The outer layer of MV membrane was often shown to 
display phosphatidylserine (PS), but this may depend on the cell type from which MVs 
derive or on the functional cell state (Connor et al. 2010). 
MVs are released during cell stress conditions after activation of cell surface receptors or 
during apoptosis following intracellular Ca2+ increase (van der Pol et al. 2012; Baroni et al. 
2007; Kahner, Dorsam, and Kunapuli 2008). MV play a pivotal role in important biological 
processes such as membrane traffic and horizontal transfer of proteins and nucleic acids 
among neighboring cells. Indeed, MV specifically interact with cells to transfer receptors, 
ligands, mRNAs and miRNAs (Gyorgy et al. 2011). These vesicles are involved in the 
pathogenesis of rheumatoid arthritis (Boilard et al. 2010), in tumour pro-invasive activity 
(Giusti et al. 2008) and in neoplastic transformation (Antonyak et al. 2011). 
MV were deeply studied in coagulation. Upon exposure to collagen, platelets release MV 
coated with tissue factor which binds its surface ligand (for example P-selectin1) on 
macrophages (Polgar, Matuskova, and Wagner 2005), neutrophils (Pluskota et al. 2008) and 
other platelets. 
An increased amount of MV was observed in plasma from patients with anti-phospholipid 
syndrome (Asherson’s syndrome) (Ardoin, Shanahan, and Pisetsky 2007) as well as in 
inflammatory conditions (Distler et al. 2005).  
Cells dying by apoptosis undergo several stages: they start with condensation of the nuclear 
chromatin, followed by membrane blebbing and progress to disintegration of the cellular 
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content into membrane vesicles known as apoptotic bodies (AB). AB are 1-5 μm in 
diameter similarly to the size range of platelets (Hristov et al. 2004). They are PS positive 
and they have a density between 1.16 to 1.29 g/ml, partially overlapping with exosome 
density and a morphology that is heterogeneous when compared with other vesicles 
visualized by TEM (van der Pol et al. 2012). 
 
Isolation and characterization methods 
 
EV studies are hampered by lack of a standardized protocol to isolate the different vesicle 
types both from cell culture and biological fluids.  
The widely accepted protocol is based on differential centrifugations which represents the 
gold standard method. In general, the isolation procedure includes a first centrifugation step 
(200-1,500 × g) to eliminate cells and cellular debris followed by a stronger centrifugation 
(10,000-20,000 × g) to eliminate vesicles with a bigger size (100-800 nm). A higher speed 
centrifugation (100,000 – 200,000 × g) is able to pellet EXO (Mathivanan, Ji, and Simpson 
2010; Thery et al. 2006).  
To better purify pellets, EVs can be loaded on sucrose gradient or cushions. Other systems 
include immunoaffinity isolation and nanomembrane ultrafiltration concentrator 
(Cheruvanky et al. 2007; Grant et al. 2011). Since vesicles are heterogeneous, there is no 
system able to accurately separate a specific type. Furthermore, isolation methods are based 
on size, sedimentation, density, and surface molecules, but there is no consensus about 
these specific characteristics for each subpopulation of EVs. The isolation efficiency 
depends on the shape and viscosity of solution, as well as on temperature, centrifugation 
time and the rotor type used for the centrifugation (van der Pol et al. 2012). The study of 
EV with TEM (transmission electron microscope) allows to more specifically identify the 
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different EV, but the sample preparation can alter their morphology (van der Pol et al. 
2012). Some studies proposed the use of atomic force microscope to detect a higher number 
of vesicles (Ashcroft et al. 2012).  
The most spread technique to characterize EV is the immunophenotyping by flow 
cytometry. Despite being limited by instrumental sensitivity, flow cytometry remains the 
most widely used method to simultaneously assess physical parameters and the presence of 
membrane markers. Using a specific panel of antibodies, this method is able to evaluate the 
cellular origin of the different populations. The use of flow citometry needs precise 
instrument calibration before EV analysis. Size beads of different diameters can be used to 
evaluate EV size (Simak and Gelderman 2006).  
The relative amount of EVs in a sample can be determined using TruCountTM tubes (Becton 
Dickinson) containing a known number of beads. 
 
Characterization of plasma EVs and sources of variability 
 
Different subpopulations of extracellular vesicles were reported in blood. Many studies 
documented the EV number variation in different pathologies and support their use as 
diagnostic or prognostic biomarkers. With regard to the erythroid compartment, it is well 
known that mature red blood cells shed EVs during eryptosis (a form of erythroid cellular 
stress) and that reticulocytes eliminate the nucleus and other cellular compartments through 
vesiculation (Griffiths et al. 2012; Ghashghaeinia et al. 2012). No data were available on 
EV production from erythroid progenitors or early precursors. 
Previous studies have shown different causes of variability that may affect the 
characterization of the EV obtained from plasma (Ayers et al. 2011). The pre-analytical 
variables that need to be considered are: the diameter of needle used for sample collection, 
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way of blood collection (vacutainer, syringe, tube) and type of anticoagulant, storage 
temperature, freeze-thaw cycles (Gyorgy et al. 2011; Simak and Gelderman 2006). It is well 
known that the use of needles with different diameters may influence the cellular stress 
with a consequent alteration in EV production. 
Among the different anticoagulants the most used is the sodium-citrate which is a reversible 
inhibitor of Ca2+. 
The main factor that influence the amount of EVs and the expression of certain markers, is 
the elapsed time between collection of peripheral blood and the first centrifugation to get 
free platelets plasma. To avoid the increase of EVs, mainly from platelets, the sample has to 
be processed in the shortest possible time (Jayachandran et al. 2012). 
Although limited variations of temperature does not heavily hamper EV isolation, freezing 
alters both number and the immunophenotype of already isolated EVs. EV sample remains 
stable for 3-4 days at room temperature (Jayachandran et al. 2012). Moreover, the number 
of Annexin-V positive EVs increases after several freeze-thaw steps (Connor et al. 2010).  
Besides pre-analytical also analytical variables have to be considered. The differential 
centrifugation based protocol allows to better separate the different EV populations but the 
increase of steps can have a  negative impact on their numbers. 
In conclusion, in order to obtain comparable samples the precise standardization of the pre-
analytical and analytical components is needed. 
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Methods 
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DBA cell model 
 
CD34+ cell culture and transduction 
 
Cord blood samples were collected from healthy donors after informed consent 
(Department of Public Health and Pediatric Sciences, University of Turin).  
Peripheral blood mononuclear cells were isolated with Ficoll-Paque™ Premium (GE 
Healthcare). Human CD34+ cells were isolated from mononuclear cord blood cells 
according to MACS® CD34 MicroBeads Kit protocol (Miltenyi). The CD34+ cells were 
maintained in culture for 4 days in SFEM medium (StemSpan® Serum-Free Expansion 
Medium) with the addition of the following cytokines to induce erythroid differentiation: 
SCF (20ng / ml), IL-3 (10ng / ml) and EPO (2U / ml) (ImmunoTools). 
On day 4, CD34+ cells were transduced with third-generation lentiviral vectors (Follenzi et 
al. 2000) expressing shRNA SCR or shRNA RPS19 (Miyake et al. 2005) with an MOI 
equal to 70. Transduction efficiency was evaluated after three days by detection of GFP 
with a FACSCalibur flow cytometer (BD Biosciences). On day 4 from transduction the 
cells were collected and processed for RNA and proteins extraction to evaluate RPS19 
haploinsufficiency. Furthermore, the supernatant of cell culture was processed to isolate 
EVs.  
 
 Western Blot analysis 
 
Cells were lysed in Lysis Buffer (50mM Tris-HCl pH 7.5, 1mM EDTA, 150mM NaCl, 1% 
NP40) supplemented with protease inhibitors (1mM PMSF, 1µg/ml Leupeptin, 0,5µg/ml 
Aprotinin, 1µg/ml Pepstatin). Cell debris was removed by centrifugation at 13,000 g for 10 
min and the supernatant was collected. Protein concentration was measured by Bradford 
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reagent (Bio-rad). Protein samples were prepared by addition of Laemli Sample buffer and  
separated on 12% SDS–PAGE, transferred on nitrocellulose membrane (BioRad) and 
incubated with primary monoclonal antibodies specific for RPS19 (Abnova), CD71 
(Abnova), p21, p53 and GAPDH (Santa Cruz Biotechnology). Detection of immunoblots 
was carried out with Western Lightning® Plus-ECL (PerkinElmer). Downregulation or 
overexpression of the proteins of interest was estimated after normalization to the intensity 
of GAPDH. Quantification analysis was performed by using ImageJ 1.43u software. 
 
qRT-PCR 
 
Total RNA was isolated from CD34+ cells using RNeasy Plus Mini kit (Qiagen) and 
reverse transcribed with a High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). TaqMan® Gene Expression assay (Applied Biosystems) was performed to 
evaluate gene expression of RPS19, TFRC (CD71) and CDKN1A (p21) using GAPDH as 
normalizator. 
 
 Extracellular vesicles 
 
 Patients and controls 
 
Peripheral blood samples were collected from DBA patients (n=13) (Table 1), patients with 
other RBC diseases (hereafter named non-DBA patients) (n=16) (Table 2) and healthy 
controls (n=22). For transfusion dependent patients, peripheral blood samples were 
collected after 2-5 weeks from the last transfusion, depending on their anemia severity.  
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 EV isolation 
 
Blood samples were collected into 3.2% sodium citrate tubes. Platelet free plasma (PFP) 
was obtained by a centrifugation at 2,400g for 10 minutes at room temperature. PFP or 
cellular surnatant were centrifuged at 1,800g for 30 minutes at 4°C. Supernatant was 
subjected to ultracentrifugation at 100,000g for 60 minutes at 4°C (OptimaTM LE-80K, 
Beckman Coulter; rotor SW60Ti, Beckman Coulter). Pellets containing isolated EVs were 
suspended in 1 mL of PBS (filtered using a 0.22 µm pore size membrane) and stored at 
4°C. 
 
 EV immunophenotypic profiles 
 
100 µL of isolated EVs were incubated for 15 minutes at 4°C in the dark with the following 
combinations of antibodies: 1) anti-IgG2A-FITC/IgG1-PE (isotypic control); 2) anti-CD71-
FITC and anti-CD34-PE (this mixture was expected to identify vesicles from BFU-E to 
ortochromatic erythroblast); 3) anti-CD71-FITC, anti-CD34-PerCP and anti-CD235a-PE 
(this mixture was expected to identify vesicles from late progenitors to mature 
erythrocytes). After a washing step with filtered PBS, EVs were resuspended in 400 µL of 
Annexin-V buffer and 2.5 µL of Annexin-V were added to the mixes 2 and 3. All reagents 
for the immunophenotypic analysis were purchased from Becton Dickinson (BD). A 
FACSCanto II flow cytometer (BD) with FacsDiva software (BD) was used for data 
acquisition. Standard size micro beads of 1 and 2 µm (Flow Cytometry Size Calibration 
Kit, Invitrogen) were used to calibrate the instrument. We have set the EV dimensional gate 
to analyse events between 500nm and 1000nm. Gate positioning was performed evaluating 
the median corresponding to 1000nm microbeads and exploiting the direct proportionality 
between the scattered light and the dimension (Figure 7).  
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The relative amount of EVs per samples was determined using the TruCountTM tubes (BD), 
according to the formula: (number of events in specific gate/ number of TruCount events) * 
(number of TruCount beads per test/ test volume)* dilution factor. Statistical analyses were 
performed using Mann-Whitney and Kruskal-Wallis tests. The potential diagnostic value of 
the assay was evaluated with the assessment of Receiver Operation Curve (ROC). An AUC 
of 1 represents an excellent test; an AUC of 0.5 represents a test that fails to discriminate 
between the two groups under study. A rough guide for classifying the accuracy of a 
diagnostic test is the traditional academic point system: 90-100% = excellent, 80-90% = 
good, 70-80% = fair, 60-70% = poor, 50-60% = fail 1 (Zhou and Harezlak 2002)  
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Results and Discussion 
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 Immunophenotypic analysis of EVs in ribosomal stress  
 
The aim of this part of the thesis was to develop a simple and rapid assay which might 
support DBA diagnosis. As an innovative approach, we studied immunophenotypes of 
erythroid EVs.  
We studied EVs by flow cytometry, which provides information both on vesicle dimensions 
and immunophenotypic properties. Our differential centrifugation-based protocol allows us 
to obtain a heterogeneous population composed by EXO, MV and the smallest AB 
(Vizziello et al., 2009). Vesicles in the size range of 500nm to 1000nm (EV dimensional 
gate) were used in this study (Figure 7). This size range, due to the instrument sensitivity 
limit, comproses a heterogeneous population of EVs including both MV and relatively 
small AB and excluding EXO . 
To characterize eryhtroid EVs, the following markers were chosen: CD34, CD71 e CD235a 
(Figure 12). Moreover, Annexin V was used to evaluate the presence of phospatidilserine.  
Isotypic control IgG2A/IgG1 was used as negative control to set the fluorescence.  
 
 
 
Figure 7. EV dimensional gating strategy. Beads with two diameters (1 and 2 µm) are shown. The 
beads were analysed in FSC vs SSC plot and in FSC vs number of events histogram. The right panel  
show the application of the EV dimensional gate on a representative control sample. Standard size 
beads were not intermixed with the sample. 
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In the first phase of the project this procedure was set up on our DBA cell model, and 
subsequently it was translated on plasma EVs from DBA patients compared to non-DBA 
patients and healthy controls. 
 
 
Assessment of DBA cell model in RPS19-depleted CD34+ cells   
 
As a proof of concept we assessed EV production in RPS19-depleted CD34+ cells. Healthy 
donors’ CD34+ cells, cultured in the presence of EPO, were transduced with a third 
generation lentiviral vectors expressing shRNA SCR or shRNA RPS19 with an MOI of 70. 
Transducion efficiency, measured as GFP expression, was on average 80%.  
Gene expression of RPS19, TFRC and CDKN1A were evaluated to validate the DBA 
cellular model. Downregulation of RPS19 was evaluated in qRT-PCR and Western Blot 
analysis (Figure 8 and Figure 9). The level of RPS19 transcript and protein was reduced to 
about 50% thus, mimicking the RP haploinsufficiency showed by DBA patients. As shown 
in Figure 8, TFRC gene expression was halved in RPS19-downregulated cells compared to 
the control. Accordingly, Western Blot analysis showed a reduction of 50% of CD71 
(Figure 9). These findings were in agreement with previous data indicating that RPS19 
haploinsufficiency induced a defect in erythroid differentiation (Dutt et al. 2011). 
Moreover, the densitometry analysis of Western Blot revealed that p53 was enhanced 1,5 
fold in RPS19-downregulated cells compared to the control (Figure 9). The increased 
stability of p53 was consistent with the pro-apoptotic phenotype due to the ribosomal stress. 
On the other hand, the activation of p53 was evaluated by analyzing its target p21. In 
particular, CDKN1A showed a fold change of 3 by qRT-PCR corresponding to an increase 
about 2,2 fold of p21 by densitometry analysis of Western Blot (Figure 8 and Figure 9). 
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In conclusion, we validated our DBA cell model by confirming RPS19-downregulation, the 
increase of p53 and its target p21 and the block of erythroid maturation.  
 
 
 
Figure 8. Validation results by qRT-PCR. Fold change of the expression of  three altered genes in 
RPS19-depleted CD34+ cells compared to scrambled control (set equal to 1). Data were obtained by 
qRT-PCR measurement and normalized to GAPDH. *p value < 0.05. Average of three experiment is 
shown. 
 
 
 
 
Figure 9. A Western Blot analysis in CD34+ cells treated with EPO and transduced with LV shRNA 
SCR or shRNA RPS19. 15µg of total proteins were loaded on each lane. B Densimotery analysis of 
Western Blot performed by using ImageJ 1.43u software. The signal of protein of interest was 
normalized to GAPDH and compared to SCR control.    
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Immunophenotypic analysis of EVs in RPS19-depleted CD34+ cells 
 
Immunophenotypic analysis of EVs isolated from DBA cellular model revealed two distinct 
populations: CD71+/CD34- and CD34+/CD71+ (Figure 10 and Figure 11). These EV 
pupulations derived from distinct stages of erythroid differentiation (BFU-E e CFU-E, 
Figure 1 and Figure 12). Our DBA cell model was maintained in culture less than 10 days. 
This time was not sufficient to complete erythroid differentiation and this is consistent with 
the early maturity of EV we observed. 
The number of events CD71+/CD34- and CD34+/CD71+ was double in the DBA cell 
model (EPO shRNA RPS19) compared to the control (EPO shRNA SCR) (Figure 10  and 
Figure 11). 
During pro-apoptotic stress, EV production often anticipates the final stages of cell death 
and the formation of AB (Simak & Gelderman, 2006). Thus, this enhancement may be due 
to the increased production of AB by cells undergoing ribosomal stress.  
 
 
A        B       
           
Figure 10. Flow citometry analysis of EVs isolated from CD34+ cells treated with EPO and 
transduced with LV shRNA SCR. A Analysis of  mixture 1 containing isotype control. The gate 
show positivity to CD71. B Analysis of mixture 2. Two distinct EV populations are gated: 
CD71+/CD34- and CD34+/CD71+. 
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A       B       
  
 
Figure 11. Flow citometry analysis of EVs isolated from CD34+ cells treated with EPO and 
transduced with LV shRNA RPS19. A  Analysis of mixture 1 containing isotype control. The gate 
show positivity to CD71. B Analysis of mixture 2. Two distinct EV populations are gated: 
CD71+/CD34- and CD34+/CD71+. 
 
These findings supported the presence of quantitative differences between two EV 
erythroid populations in the RPS19-downregulated cells compared to the control. 
 
Immunophenotypic profiling of erythroid progenitor-derived EVs in DBA: a 
new diagnostic strategy 
 
The evidence of distinct EV populations in our DBA cell models supported the analysis of 
erythroid EVs in plasma derived from three groups of individuals: DBA patients, non-DBA 
patients and healthy controls (Table 4, Table 5, Table 6). The aim of this study was to 
evaluate if EV populations in the peripheral blood of DBA patients can be leveraged as a 
potential diagnostic tool.  
 
54
  
 
 
 
 
Figure 12. Simplified scheme of erythropoiesis. The most representative markers expressed 
during erythroid maturation steps are indicated. The intensity colour variation corresponds to 
expression levels. 
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Table 4: Clinical characteristics of DBA patients (*patient in clinical remission; **two analysis performed in two independent samples; ┼three different analysis a 
few years apart; ▲two different analysis a few years apart). The ranges of PB BFU-E BASAL and BM BFU-E BASAL of healthy individuals are 16.0+/-8.0 and 
57.0+/-28, respectively. The normal range of e-ADA is 0,8-1,2 U/g Hb. 
 
 
 
 
 
 
DBA 
PATIENTS 
SEX AGE 
AGE 
AT 
ONSET 
TREATMENT Hb (g/dL) MCV (fL) 
RBC 
(10^6/uL) 
Reticulocytes 
(10^9/L) 
eADA 
(U/g Hb) 
BM 
BM BFU-E  
BASAL 
BM BFU-E  
WITH SCF 
PB BFU-E 
BASAL 
PB BFU-E 
WITH SCF 
1 M 24 
2 
months TRANSFUSION 8.0 88.8 3.04 13.5 
 
3.2 
ERYTHROID 
APLASIA 0 46 0 1 
2 F 43 
At birth 
STEROIDS 10.7 89.8 3.54 N/D 
 
3.9 
ERYTHROID 
HYPOPLASIA N/D N/D 1 7 
3 M 7 
1 month 
TRANSFUSION 6.8; 6.8** 80.9; 70.8** 2.34; 2.39** 2.8; 5.1** 
 
N/D 
ERYTHROID 
HYPOPLASIA 23 26 1 8 
4 M 5 
1 year 
TRANSFUSION 9.5 79.8 3.20 10.7 
 
N/D 
ERYTHROID 
APLASIA 0 0 N/D N/D 
5 F 27 
2 
months NONE* 10.9 83.8 3.78 45.8 
 
5.3 
ERYTHROID 
APLASIA 0 7 N/D N/D 
6 F 4 
At birth 
TRANSFUSION 9.6 82.1 3.36 6 
 
N/D 
ERYTHROID 
APLASIA 0; 5; 20┼ 2; 74; 46┼ 0; 0▲ 0; 2▲ 
7 M 37 
1 year 
NONE* 11.7 106.8 3.27 35.7 
 
4.1 
ERYTHROID 
HYPOPLASIA 7 41 N/D N/D 
8 F 5 
6 
months TRANSFUSION 6.2 81.8 2.12 11.6 
 
2 N/D N/D N/D N/D N/D 
9 F 17 
3 
months STEROIDS 11.5 99.6 3.30 42.8 
 
2.6 
ERYTHROID 
APLASIA 0; 5▲ 62; 54▲ N/D N/D 
10 M 13 
2 
months STEROIDS 12.6 91.4 4.06 105.0 
 
3.4 
ERYTHROID 
APLASIA 12 89 N/D N/D 
11 M 12 
2 
months TRANSFUSION 9.0 81.9 3.20 17.7 
 
N/D NORMAL N/D N/D N/D N/D 
12 M 20 
1 year 
NONE 15.2 89.7 4.8 62.3 
 
5 
ERYTHROID 
HYPOPLASIA 0; 0▲ 2; 52▲ N/D N/D 
13 M 25 
4 
months TRANSFUSION 10.1 85.6 3.4 45 
 
N/D 
ERYTHROID 
APLASIA N/D N/D N/D N/D 
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NON-DBA PATIENTS SEX AGE TREATMENT Hb (g/dL) MCV (fL) RBC (10^6/uL) Reticulocytes (10^9/L) DISEASE 
23 F 7 NONE 13.3 67.6 5.74 44.8 Heterozygous for Beta Thalassemia 
24 M 4 IRON 12.0 80.5 4.16 69.9 Iron deficiency anemia  
25 M 1 NONE 12.2 70.6 4.96 55.7 Heterozygosis for Hb S 
26 M 5 NONE 9.0 62.3 4.45 47 Iron refractory anemia 
27 M 9 TRANSFUSION 9.9 88.0 2.98 33.5 Congenital dyserythropoietic anemia type II (CDA II) 
28 M 12 NONE 14.4 85.6 4.69 110.5 Spherocytosis (Splenectomized) 
29 M 20 NONE 17.5 88.9 5.26 80.4 Acquired erytrocytosis 
30 M 4 NONE 10.8 67.8 4.85 118.1 Iron deficiency anemia 
31 F 7 months NONE 8.2 76.3 3.19 64.9 Homozygous for Beta thalassemia 
32 M 15 CYCLOSPORIN,  STEROIDS  6.7 92.0 2.09 28.9 Aplastic anemia 
33 F 8 STEROIDS 9.9 85.4 3.4 44.7 Aplastic anemia 
34 F 14 NONE 9.1 85.0 3.19 56.4 Congenital dyserythropoietic anemia type II (CDA II 
35 M 10 NONE 13.0 95.3 3.86 82.1 Fanconi Anemia 
36 M 10 NONE 13.0 77.1 4.97 77.3 Lymphadenitis 
37 M 12 NONE 13.4 75.4 4.88 N.D Thrombocytopenia 
38 M 13 MYCOPHENOLATE 14.7 77.0 5.50 64.6 Autoimmune lymphoproliferative syndrome (ALPS) 
 
Table 5: Clinical characteristics of non-DBA patients (ATGT: Anti Thymocyte Globulin Treatment).
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The markers we used were chosen to identify EVs derived from erythroid progenitors 
(CD34, CD71), erythroid precursors (CD71, CD235a) and cells in the late stage of 
erythroid maturation, i.e reticulocytes and erythrocytes (CD235a) (Figure 1 and Figure 12). 
Figure 13 shows EVs from healthy controls grouped into the following categories: EVs 
shed from late erythroid progenitors (CD34+/CD71low/CD235alow/PS+), erythroid 
precursors (CD71+/CD34-/CD235alow/PS-), and cells of late erythroid stages, e.g. 
reticulocytes and erythrocytes (CD71-/CD235a+/CD34-. About 60% of this population was 
PS+). The bulk of these EVs are likely derived from the peripheral blood because if the 
detected EVs derived also from BM, EV populations derived from all types of erythroid 
progenitors and precursors would be expected. For example, we have not detected a 
CD71high/CD235alow population, expected to be shed from orthochromatic erythroblasts.  
 
 
 
Figure 13. EV distribution in dot plot graphs obtained from the acquisition of the samples incubated 
with anti-CD71-FITC, anti-CD34-PerCP, anti-CD235a-PE and Annexin V-APC. Only the events 
occuring in the EV dimensional gate were included. Three EV clusters were identified and indicated 
with different colours. 
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Comparison of experiments with and without anti-CD235a antibody showed that 
CD71+/CD34-/PS- and CD34+/CD71low/PS+ populations corresponded to the 
CD71+/CD34-/CD235alow/PS- and CD34+/CD71low/CD235alow/PS+ populations, 
respectively (vesicles obtained using or not the antibody against CD235, were counted and 
their numbers corresponded) (Figure 14, Table 6).  
 
 
Figure 14. EV distribution in a dot plot graph comparing CD71 and CD34 markers of the 
events occuring in the EV dimensional gate. CD71+/CD34- (corresponding to CD71+/CD34-
/CD235alow/PS-) and CD34+/CD71low (corresponding to CD34+/CD71low/CD235a+/PS+) 
populations are shown in representative subjects (healthy controls, DBA patients and non-DBA 
patients). Comparison of EV populations obtained with or without CD235a staining is shown.  
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Consequently, we reasoned that the mixture without CD235a was more suitable for 
diagnostic purposes because it was not influenced by these technical concerns.  
 
 
HEALTHY CONTROLS 
CD34+/CD71low 
 (without CD235a staining) 
CD34+/CD71low  
(with CD235a staining) 
1 0,8 1,0 
2 2,6 3,0 
3 17,8 14,4 
4 5,9 3,2 
5 1,6 2,8 
6 2,2 2,8 
7 4,9 3,4 
8 1,7 2,4 
9 5,2 3,1 
10 2,2 2,0 
11 3,8 5,4 
12 1,3 1,0 
13A 6,2 5,3 
13B 1,4 1,7 
14 4,2 2,8 
15A 15,9 13,2 
15B 2,9 2,5 
16 4,5 3,1 
17 6,4 3,5 
18 2,4 2,6 
19 5,3 2,5 
20 1,7 2,1 
21 17,1 10,4 
22 4,5 3,6 
NON-DBA PATIENTS 
CD34+/CD71low 
 (without CD235a staining) 
CD34+/CD71low  
(with CD235a staining) 
23 6,5 4,3 
24 4,8 3,4 
25 1,2 2,4 
26 0,6 1,3 
27 3,6 4,3 
28 1,4 1,5 
29 2,1 3,1 
30 1,5 2,1 
31 2,4 3,6 
32 4,8 4,4 
33 0,8 1,3 
34 1,1 0,7 
35 4,0 4,9 
36 1,4 1,9 
37 4,1 3,2 
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38 4,5 4,9 
DBA PATIENTS 
CD34+/CD71low 
 (without CD235a staining) 
CD34+/CD71low  
(with CD235a staining) 
1A 0,7 0,6 
1B 0,4 0,8 
2 0,7 0,8 
3 0,8 1,2 
4 0,8 0,8 
5 0,4 0,6 
6 0,4 0,9 
7 1,6 1,2 
8 0,8 0,7 
9 0,6 0,6 
10 4,3 2,6 
11 1,2 1,4 
12 6,4 4,3 
13 2,7 3,6 
 
Table 6: Absolute number of CD34+/CD71low population obtained from the three groups analyzed 
without or with CD235a staining, respectively (*A, B indicate the analysis performed on the same 
control or patient in two independent samples). 
 
When we started this work PS was considered as the main marker of EVs. Current data  
indicate that EVs populations derived from different cells may be PS+ or PS- (Ayers et al. 
2011). In our experiments, its presence was not helpful in the discrimination of EV 
population derived from DBA patients compared to controls. 
When we tested DBA patients, only the CD34+/CD71low/PS+ population (hereafter named 
CD34+/CD71low) was significantly different when compared to other groups. This 
population, representing late erythroid progenitors was substantially reduced in 8/13 DBA 
patients relative to healthy controls. Among patients with other haematological disorders, 
15/16 patients showed a proportion of EVs derived from erythroid progenitors similar to 
controls (Figure 14). The median difference between DBA patients and all the other 
individuals (non-DBA patients + healthy controls) was statistically significant (p<0.05, 
Mann-Whitney Test) as was the difference between DBA patients and each of the other 
groups when compared separately (p<0.05, Kruskal-Wallis Test; Figure 15). As expected, 
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the difference of medians comparing non-DBA patients vs healthy controls was not 
statistically significant (Figure 15). Finally the CD71-/CD34-/CD235a+ EV population, that 
is shed from the late stage of maturation, represents the bulk of events. It should be noted 
that in all transfusion dependent patients, either DBA or non-DBA, this population includes 
also EVs shed from donor cells. Consequently, we could not compare this population 
among the three groups analysed.  
 
 
 
Figure 15. ROC curves analysis of CD34+/CD71low population. ROC curves evaluating the 
accuracy (AUC) of the CD34+/CD71low analysis in the discrimination of (A) DBA patients vs 
healthy controls (B) DBA patients vs all the others (healthy controls + non-DBA patients) (C) DBA 
patients vs non-DBA patients (D) non-DBA patients vs healthy controls. * p-value <0.01. 
 
The area under the ROC curve (AUC) that compares DBA patients vs healthy controls was 
0.84 (= good) while the AUC of DBA patients vs all the other individuals was 0.80 (= 
good). Moreover, comparison between DBA patients and non-DBA patients produced an 
AUC of 0.75 (= fair). In all comparisons the cluster was able to distinguish the groups 
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under study with a p-value< 0.01. As expected the AUC that plotted non-DBA patients and 
healthy controls was 0.66 (= poor), consequently this assay cannot discriminate between 
these groups (Figure 15). 
AUC values suggest that this test has a good accuracy to discriminate DBA patients from 
healthy controls, and/or from non-DBA patients. The CD34+/CD71low EV population is 
expected to be shed from BFU-E progenitors and our results are in agreement with the low 
levels of BFU-E found in DBA patients (Table 4). 
Actually, this population seems to reflect more the bone marrow BFU-E numbers than the 
level of anemia or the disease type. According to this hypothesis, 3 DBA patients (#7, #10, 
#12), who show this population, had normal erythropoiesis at the time of this analysis 
(Table 4).  In contrast, we found a single DBA patient (#11) with anemia at the time of this 
analysis who showed normal levels of this EV population without an evident explanation.  
On the other hand, all but one patient with other haematological diseases clustered in the 
healthy control range. This cluster includes six patients with congenital anemias 
characterised by erythroid cell loss at a stage that is later than BFU-E (i.e. HbS, 
spherocytosis, CDA II and Beta thalassemia), and five patients with acquired conditions 
(Table 5). We also analysed a patient with Fanconi Anemia which can have overlapping 
features with DBA. 
Patient #26 is the only non-DBA patient who did not show this population. He is affected 
by an iron refractory anemia with severe microcytosis. We expect that this patient also has a 
defect of erythroid progenitors, but a BM evaluation has not been performed so far.  
Overall these data suggest that the EV assay we devised may be useful to improve DBA 
diagnosis as a quicker and less invasive alternative to BFU-E cultures.  
 
This study was focused on the only EV population that was able to distinguish between the 
three groups under study. Nevertheless we could also draw interesting information from the 
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other EV populations we characterize. As expected, the majority of EVs derived from 
circulating reticulocytes and erythrocytes. It was demonstrated that transition between 
reticulocyte R1 and R2 comprised plasma membrane rearrangements with loss of EV 
CD235a+ (Griffiths et al. 2012). Surprisingly, in some individuals (DBA patients: #1,#3,#4 
and healthy controls: #15) this EV populations also showed a variable positivity to CD71 
(Figure 16).  
 
Figure 16. Qualitative analysis of EVs from late erythroid differentiation. Dot plot graphs 
comparing CD71 and CD235a markers (mixture 3) are reported. The variable positivity to CD71 of 
EV CD235a+ is shown in control #15 and DBA patients #1, #3, #5 compared to control #1.   
 
It is well known that during the reticulocyte maturation, CD71 is downregulated through 
EV production because iron uptake is not required anymore (Harding and Stahl 1983; Ney 
2011). In conclusion, we speculated that the circulating cells in the last stages of 
differentiation might not completely loose CD71 in some individuals.  
  
DBA model vs DBA patients  
 
The results obtained from DBA cell model and from plasma of patients showed some 
differences that may be mainly attributable to in vitro and in vivo environments, 
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respectively. We found an increased number of events in our DBA cell model compared to 
the control in contrast with the results found in DBA patients. It is likely that the increased 
number of EV produced by CD34+ shRNA RPS19 compared to CD34+ shRNA SCR was 
due to the enhanced production of smaller AB. In vivo, the majority of these AB may be 
fastly fagocitated by the reticuloendothelial system. Nonetheless, we cannot exclude that 
LV transduction may contribute to the enhancement of AB observed in DBA model.  
Moreover, the model system was able to evaluate the first phase of erythroid differentiation 
whereas the analysis performed on plasma was the result of the entire differentiation 
process. 
In conclusion, our DBA cell model was useful to set the EV analysis but did not 
recapitulate the in vivo situation. 
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Abstract
Diamond-Blackfan Anaemia (DBA) is a rare inherited anaemia caused by heterozygous
mutations in one of 13 ribosomal protein genes. Erythroid progenitors (BFU-E and CFU-E)
in bone marrow (BM) show a proapoptotic phenotype. Suspicion of DBA is reached after
exclusion of other forms of BM failure syndromes. To improve DBA diagnosis, which is con-
firmed by mutation analysis, we tested a new approach based on the study of extracellular
vesicles (EVs) isolated from plasma by differential centrifugations and analysed by flow
cytometry. We chose CD34, CD71 and CD235a markers to study erythroid EVs. We char-
acterised the EVs immunophentoypic profiles of 13 DBA patients, 22 healthy controls and
16 patients with other haematological diseases. Among the three EVs clusters we found,
only the CD34+/CD71low population showed statistically significant differences between
DBA patients and controls (p< 0.05). The absence of this cluster is in agreement with the
low levels of BFU-E found in DBA patients. The assessment of ROC curves demonstrated
the potential diagnostic value of this population. We suggest that this assay may be useful
to improve DBA diagnosis as a quicker and less invasive alternative to BM BFU-E culture
analysis.
Introduction
Diamond-Blackfan Anaemia (DBA, OMIM 105650) is a rare inherited pure red cell aplasia
that typically presents in the first year of life with an incidence of 6–7 newborns per million live
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births. Penetrance is incomplete and expressivity widely variable even in patients from the
same family. Patients with DBA exhibit a macrocytic normochromic anaemia and reticulocyto-
penia [1]. Approximately 40% of patients display additional clinical abnormalities such as cra-
niofacial, thumb, kidney and heart malformations and growth retardation [2]. Erythroid
progenitors (BFU-E and CFU-E) in the patients’ bone marrow (BM) show a pro-apoptotic
phenotype and their number is reduced in most patients. The erythrocyte adenosine deaminase
(eADA) activity is elevated in 80–85% of patients, but cannot be performed in transfused
patients [3].
DBA is considered as the prototype of ribosomopathies. Heterozygous mutations in one of
13 ribosomal protein (RP) genes have been found in about 65% of patients [4]. Haploinsuffi-
ciency of ribosomal proteins leads to ribosomal stress and activation of p53–dependent and
independent pathways, which result in apoptosis and decreased proliferation [5, 6, 7]. A non-
ribosomal form of DBA due to mutations in the GATA1 erythroid-specific transcription factor
has also been reported [8, 9].
During the course of the disease, approximately 17% of all DBA patients enter spontaneous
or steroid-induced remission, defined as a state of transfusion independence for at least six
months with physiologically acceptable haemoglobin levels. The mechanism behind remission
remains unknown and about 15% of those who enter remission relapse [3].
Diagnosis of DBA is hampered by the presence of other BM failure syndromes such as Fan-
coni Anaemia (FA), Shwachman-Diamond syndrome (SDS), Dyskeratosis Congenita (DC)
and Transient Erythroblastopenia of Childhood (TEC), which can have overlapping clinical
presentations [10]. FA is excluded from a diagnosis by negative results in a chromosome break-
age assay while the absence of telomere shortening rules out DC. SDS is characterised by pan-
creatic insufficiency and often associated with skeletal malformations and neutropenia.
The absence of a unique diagnostic feature for DBA often makes DBA a diagnosis of exclu-
sion. While the identification of the underlying molecular basis for DBA in many patients has
now made diagnosis possible through genetic testing, the genes affected in approximately 35%
of suspected DBA patients remain unknown leaving a degree of diagnostic uncertainty for
these patients. Further confounding a diagnosis of DBA is the increased identification through
genetic testing of patients with non-classical forms of DBA including patients with malforma-
tions without anaemia or with anaemia presenting as an adult. Recently, we have proposed a
rapid and convenient assay readily available in diagnostic laboratories where functional defects
in ribosome synthesis linked to haploinsufficiency for large subunit ribosomal proteins could
be used as a criterion for making a DBA diagnosis [4]. This approach is currently limited to
large subunit ribosomal proteins and would only be supportive by exclusion for DBA caused
by defects in non-ribosomal protein genes.
As an alternative strategy for developing a more inclusive assay for possible use in DBA
diagnosis we turned to the study of extracellular vesicles (EVs) whose presence may be altered
as a consequence of increased apoptosis associated with many bone marrow failures and whose
characteristic molecular properties may specifically define the nature of the bone marrow fail-
ure. EVs are membrane-bound organelles released by various cell types. Their membrane dis-
plays typical markers of the parental cell of origin. Microvesicles (MV) have a diameter of 50-
1000nm. MVs have not an endosomal origin and they are enclosed by plasma membrane frag-
ments [11;12]. The outer layer of MV membrane has been often shown to display phosphati-
dylserine (PS), but this may depend on the cell type from which MVs derive or on the
functional cell state [13]. Apoptotic bodies (ABs) are 1–5 μm in diameter. They are released as
blebs by cells undergoing apoptosis and they are PS positive.
MVs play a pivotal role in important biological processes such as membrane traffic and hor-
izontal transfer of proteins and nucleic acids among neighboring cells [14]. With regard to the
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erythroid compartment, it is well known that mature red blood cells shed EVs during eryptosis
(a form of erythroid cellular stress) and that reticulocytes eliminate the nucleus and other cellu-
lar compartments through vesiculation [15]. No data are available on EV production from ery-
throid progenitors or early precursors. Classification of EVs, their isolation protocol and
detection, molecular details of their release, clearance and biological function are still under
intense investigation [16, 17].
In the present study we focused on the immunophenotypic characterization of erythroid
EVs from plasma of three different groups of individuals: DBA patients, patients with other
haematological diseases, and healthy controls. We reasoned that erythroid EVs may vary in the
peripheral blood of DBA patients as a consequence of the loss of erythroid progenitor cells in
the marrow of these patients. To our knowledge, this is the first attempt to use EVs in the
peripheral blood as an assay for marrow failure and to use EVs as a potential diagnostic tool for
Diamond-Blackfan Anaemia.
Three markers were used to characterise EVs derived from cells of the erythroid lineage:
CD34, CD71 and CD235a. CD34 is the main haematopoietic stem cell marker. CD71 is trans-
ferrin receptor 1, which is essential for iron uptake and consequently for haemoglobin synthe-
sis during erythroid differentiation (progenitors, i.e. BFU-E, CFU-E and early precursors, i.e
proerythroblast, basophilic erythroblast, polychromatophilic erythroblast and orthochromatic
erythroblast). Finally, CD235a, i.e. glycophorin A, is the erythroid specific marker and it is
expressed by erythroid precursors, i.e proerythroblast, basophilic erythroblast, polychromato-
philic erythroblast, orthochromatic erythroblast, reticulocytes and erythrocytes (Fig 1) [18, 19].
Additionally, the presence of PS (e.g a marker of ABs and certain MV types) was tested by
Annexin-V binding.
Methods
Ethical Statement
The ethical committee of Regina Margherita Children's Hospital (Turin) approved the use of
blood samples for diagnostic procedures. A written informed consent was signed by all the
individuals under study or their parents, caretakers, or guardians on behalf of the minors/
children.
Patients and controls
Peripheral blood samples were collected from DBA patients (n = 13) (Table 1), patients with
other haematological diseases (hereafter named non-DBA patients) (n = 16) (Table 2) and
healthy controls (n = 22) (S1 Table). For transfusion dependent patients, peripheral blood sam-
ples were collected after 2–5 weeks from the last transfusion, depending on their anaemia
severity.
EV enrichment
Blood samples were collected into 3.2% sodium citrate tubes. Platelet free plasma (PFP) was
obtained by a centrifugation at 2,400g for 10 minutes at room temperature. PFP was then cen-
trifuged at 1,800g for 30 minutes at 4°C. Supernatant was subjected to ultracentrifugation at
100,000g for 60 minutes at 4°C (OptimaTM LE-80K, Beckman Coulter; rotor SW60Ti, Beckman
Coulter). Pellets containing EVs were suspended in 1 mL of PBS (filtered using a 0.22 μm pore
size membrane) and stored at 4°C.
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Fig 1. Simplified scheme of erythropoiesis. The most representative markers expressed during erythroid maturation steps are indicated. The intensity
colour variation corresponds to expression levels.
doi:10.1371/journal.pone.0138200.g001
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EV immunophenotypic profiles
100 μL of resuspended EVs were incubated for 15 minutes at 4°C in the dark with the following
combinations of antibodies: 1) anti-IgG2A-FITC/IgG1-PE (isotypic control); 2) anti-
CD71-FITC and anti-CD34-PE (this mixture was expected to identify vesicles from BFU-E to
ortochromatic erythroblast); 3) anti-CD71-FITC, anti-CD34-PerCP and anti-CD235a-PE (this
mixture was expected to identify vesicles from late progenitors to mature erythrocytes). After a
washing step with filtered PBS, EVs were resuspended in 400 μL of Annexin-V buffer and
2.5 μL of Annexin-V-APC were added to the mixes 2 and 3. All reagents for the immunophe-
notypic analysis were purchased from BD. A FACSCanto II flow cytometer (BD) with FacsDiva
software (BD) was used for data acquisition. Standard size micro beads of 1 and 2 μm (Flow
Cytometry Size Calibration Kit, Invitrogen) were used to calibrate the instrument. We have set
the EV dimensional gate to analyse events between 500 nm and 1000 nm. Gate positioning was
performed evaluating the median corresponding to 1000nm microbeads and exploiting the
direct proportionality between the scattered light and the dimension (Fig 2, upper left panel
and S2 Fig).
The relative amount of EVs per samples was determined using the TruCountTM tubes (BD),
according to the formula: (number of events in specific gate/ number of TruCount events) 
(number of TruCount beads per test/ test volume) dilution factor. Statistical analyses were
performed using Mann-Whitney and Kruskal-Wallis tests.
ROC curves
Receiver operating characteristic (ROC) curves were established to evaluate the potential diag-
nostic value of the EV analysis. In a ROC curve the true positive rate (Sensitivity) is plotted in
Table 2. Clinical characteristics of Non-DBA Patients.
NON-DBA
PATIENTS
SEX AGE TREATMENT Hb (g/
dL)
MCV
(fL)
RBC
(10^6/uL)
Reticulocytes
(10^9/L)
DISEASE
23 F 7 NONE 13.3 67.6 5.74 44.8 Heterozygous for Beta
Thalassemia
24 M 4 IRON 12.0 80.5 4.16 69.9 Iron deficiency anaemia
25 M 1 NONE 12.2 70.6 4.96 55.7 Heterozygosis for Hb S
26 M 5 NONE 9.0 62.3 4.45 47 Iron refractory anaemia
27 M 9 TRANSFUSION 9.9 88.0 2.98 33.5 Congenital dyserythropoietic
anemia type II (CDA II)
28 M 12 NONE 14.4 85.6 4.69 110.5 Spherocytosis (Splenectomized)
29 M 20 NONE 17.5 88.9 5.26 80.4 Acquired erytrocytosis
30 M 4 NONE 10.8 67.8 4.85 118.1 Iron deficiency anaemia
31 F 7
months
NONE 8.2 76.3 3.19 64.9 Homozygous for Beta thalassemia
32 M 15 CYCLOSPORIN,
STEROIDS
6.7 92.0 2.09 28.9 Aplastic anaemia
33 F 8 STEROIDS 9.9 85.4 3.4 44.7 Aplastic anaemia
34 F 14 NONE 9.1 85.0 3.19 56.4 Congenital dyserythropoietic
anemia type II (CDA II
35 M 10 NONE 13.0 95.3 3.86 82.1 Fanconi Anaemia
36 M 10 NONE 13.0 77.1 4.97 77.3 Lymphadenitis
37 M 12 NONE 13.4 75.4 4.88 N.D Thrombocytopenia
38 M 13 MYCOPHENOLATE 14.7 77.0 5.50 64.6 Autoimmune lymphoproliferative
syndrome (ALPS)
doi:10.1371/journal.pone.0138200.t002
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Fig 2. EV distribution in a dot plot graph comparing CD71 and CD34markers of the events occuring in the EV dimensional gate. CD71+/CD34-
(corresponding to CD71+/CD34-/CD235alow/PS-) and CD34+/CD71low (corresponding to CD34+/CD71low/CD235a+/PS+) populations are shown in
representative subjects (healthy controls, DBA patients and non-DBA patients). Comparison of EV populations obtained with or without CD235a staining is
shown.
doi:10.1371/journal.pone.0138200.g002
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function of the false positive rate (100-Specificity) for different cut-off points of a parameter.
The Area Under the ROC Curve (AUC) is a measure of the accuracy of a parameter in the dis-
crimination of two groups under study. An AUC of 1 represents an excellent test; an AUC of
0.5 represents a test that fails to discriminate between the two groups under study. A rough
guide for classifying the accuracy of a diagnostic test is the traditional academic point system:
90–100% = excellent, 80–90% = good, 70–80% = fair, 60–70% = poor, 50–60% = fail [20].
Results
EV immunophenotypic profile
The markers we used were chosen to identify EVs derived from early progenitors including
BFU-E (CD34, CD71), CFU-E (CD71), erythroid precursors (CD71, CD235a) and cells in the
late stage of erythroid maturation, i.e reticulocytes and erythrocytes (CD235a) (Fig 1). An iso-
typic control was used to set the gates of interest (S1 Fig). The immunophenotypic analysis was
performed on the events occurring only within the EV dimensional gate (Fig 2, upper panel
and S2 Fig).
S1 Fig shows EVs from healthy controls grouped into the following categories: EVs shed
from late erythroid progenitors (CD34+/CD71low/CD235alow/PS+), erythroid precursors
(CD71+/CD34-/CD235alow/PS-), and cells of late erythroid stages, e.g. reticulocytes and eryth-
rocytes (CD71-/CD235a+/CD34-. About 60% of this population was PS+). Since the anti-
CD235a-PE was prone to aggregation we evaluated whether the same EV populations could be
defined without using this antibody. Comparison of experiments with and without anti-
CD235a antibody showed that CD71+/CD34-/PS- and CD34+/CD71low/PS+ populations cor-
responded to the CD71+/CD34-/CD235alow/PS- and CD34+/CD71low/CD235alow/PS+ popula-
tions, respectively (vesicles obtained using or not the antibody against CD235, were counted
and their numbers corresponded) (Fig 2, and S2 Table). Consequently, we reasoned that the
mixture without CD235a was more suitable for diagnostic purposes because it was not influ-
enced by these technical concerns.
When we started this work PS was considered as the main marker of EVs. Current data
indicate that EVs populations derived from different cells may be PS+ or PS- [15]. In our
experiments, its presence was not helpful in the discrimination of EV population derived from
DBA patients compared to controls. When we tested DBA patients, only the CD34+/CD71low/
PS+ population (hereafter named CD34+/CD71low) was significantly different when compared
to other groups. This population, representing late erythroid progenitors was substantially
reduced in 8/13 DBA patients relative to healthy controls. Among patients with other haemato-
logical disorders, 15/16 patients showed a proportion of EVs derived from erythroid progeni-
tors similar to controls (Fig 2). The median difference between DBA patients and all the other
individuals (non-DBA patients + healthy controls) was statistically significant (p<0.05, Mann-
Whitney Test) as was the difference between DBA patients and each of the other groups when
compared separately (p<0.05, Kruskal-Wallis Test; Fig 3). As expected, the difference of medi-
ans comparing non-DBA patients vs healthy controls was not statistically significant (Fig 3).
Finally the CD71-/CD34-/CD235a+ EV population, that is shed from the late stage of matu-
ration, represents the bulk of events. It should be noted that in all transfusion dependent
patients, either DBA or non-DBA, this population includes also EVs shed from donor cells.
Consequently, we could not compare this population among the three groups analysed.
ROC curves
The assessment of Receiver Operating Characteristic (ROC) curves demonstrated the potential
use of the CD34+/CD71low population as a diagnostic tool. The area under the ROC curve
Erythroid EVs in DBA
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(AUC) that compares DBA patients vs healthy controls was 0.84 (= good) while the AUC of
DBA patients vs all the other individuals was 0.80 (= good). Moreover, comparison between
DBA patients and non-DBA patients produced an AUC of 0.75 (= fair). In all comparisons the
cluster was able to distinguish the groups under study with a p-value< 0.01. As expected the
AUC that plotted non-DBA patients and healthy controls was 0.66 (= poor), consequently this
assay cannot discriminate between these groups (Fig 4).
Discussion
The aim of this study was to evaluate if EV populations in the peripheral blood of DBA patients
can be leveraged as a potential diagnostic tool. We studied EVs by flow cytometry, which pro-
vides information both on vesicle dimensions and immunophenotypic properties. Vesicles in
the size range of 500nm to 1000nm were used in this study. This size range includes a heteroge-
neous population of EVs including both microvesicles and relatively small apoptotic bodies.
Using our approach we were able to identify EVs ranging from early erythroid progenitors
to mature erythrocytes. The bulk of these EVs are likely derived from the peripheral blood,
because if the detected EVs derived also from bone marrow EV populations, vesicles derived
from all types of erythroid progenitors and precursors would be expected.
Importantly, of the vesicle populations studied, the CD34+/CD71low cluster showed statisti-
cally significant differences between DBA patients and healthy controls or patients with other
haematological diseases (Fig 3).
The potential diagnostic value of the analysis of CD34+/CD71low EVs was assessed using
the ROC curve test. AUC values suggest that this test has a good accuracy to discriminate DBA
Fig 3. Box plot of Absolute number of events included in the CD34+/CD71low gate.Outliers are shown in black spots. Comparison between DBA
patients, non-DBA patients and healthy controls. *The difference of medians is statistically significant (p<0.05, Kruskall-Wallis test).
doi:10.1371/journal.pone.0138200.g003
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patients from healthy controls, and/or from non-DBA patients. The CD34+/CD71low EV pop-
ulation is expected to be shed from BFU-E progenitors and our results are in agreement with
the low levels of BFU-E found in DBA patients (Table 1).
Actually, this population seems to reflect more the bone marrow BFU-E numbers than the
level of anaemia or the disease type. According to this hypothesis, 3 DBA patients (#7, #10,
#12), who show this population, had normal erythropoiesis at the time of this analysis
(Table 1). In contrast, we found a single DBA patient (#11) with anaemia at the time of this
analysis who showed normal levels of this EV population without an evident explanation.
On the other hand, all but one patient with other haematological diseases clustered in the
healthy control range. This cluster includes six patients with congenital anaemias characterised
by erythroid cell loss at a stage that is later than BFU-E (i.e. HbS, spherocytosis, CDA II and
Beta thalassemia), and five patients with acquired conditions. We also analysed a patient with
Fanconi Anaemia which can have overlapping features with DBA.
Fig 4. ROC curves analysis of CD34+/CD71low population. ROC curves evaluating the accuracy (AUC) of the CD34+/CD71low analysis in the
discrimination of (A)DBA patients vs healthy controls (B) DBA patients vs all the others (healthy controls + non-DBA patients) (C) DBA patients vs non-DBA
patients (D) non-DBA patients vs healthy controls. * p-value <0.01.
doi:10.1371/journal.pone.0138200.g004
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Patient #26 is the only non-DBA patient who did not show this population. He is affected
by an iron refractory anaemia with severe microcytosis. We expect that this patient also has a
defect of erythroid progenitors, but a BM evaluation has not been performed so far.
Overall these data suggest that the EV assay we devised may be useful to improve DBA diag-
nosis as a quicker and less invasive alternative to BFU-E cultures. It should be noted that this
assay is performed from peripheral blood, is amenable to transfused patients and requires only
two working days, whereas BFU-E cultures require 15 working days and needs to be performed
using a bone marrow sample in DBA patients.
Finally, this assay could be a useful tool to select erythroid cell-derived EVs in order to study
their content and their functional role in erythroid differentiation. It may also be modified to
isolate EVs derived by other lineage specific progenitors and used to study other types of bone
marrow failure syndromes.
Supporting Information
S1 Fig. EV distribution in dot plot graphs obtained from the acquisition of the samples
incubated with anti-CD71-FITC, anti-CD34-PerCP, anti-CD235a-PE and Annexin
V-APC. Only the events occuring in the EV dimensional gate were included. Three EV clusters
were identified and indicated with different colours.
(TIF)
S2 Fig. EV dimensional gating strategy. Beads with two diameters (1 and 2 μm) are shown.
The beads were analysed in FSC vs SSC plot and in FSC vs number of events histogram. The
right panel show the application of the EV dimensional gate on a representative control sam-
ple. Standard size beads were not intermixed with the sample.
(TIF)
S1 Table. Characteristics of healthy controls.
(DOC)
S2 Table. Absolute number of CD34+/CD71low population obtained from the three groups
analyzed without or with CD235a staining, respectively. (A, B indicate the analysis per-
formed on the same control or patient in two independent samples).
(DOC)
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The main purpose of this part of my PhD project was to look for new DBA genes in a 
subset of Italian DBA patients who were already screened for the 7 RP genes (RPS10, 
RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A) that are most frequently mutated in 
DBA patients,  and for GATA1 and resulted mutation negative. 
I sequenced two genes: MCM2, a gene involved in erythropoiesis and WBSCR22, a gene 
involved in ribosome biogenesis.  
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Rationale of the project 
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MCM2 
 
This study was performed in collaboration with Dr. David Bodine (National Human 
Genome Research Institute, Genetics and Molecular Biology Branch, Bethesda, MD) and 
Dr. Jason Farrar (University of Arkansas for Medical Sciences, Little Rock, AR) who 
studied a DBA American family by next generation sequencing. The healthy parents, a 
DBA child and a healthy sibling were studied.  
A homozygous missense mutation on MCM2 (exon9: c.1501G>A; p.G501R) was found in 
the patient, whereas her brother was wild type and the parents heterozygous (O’Brien et al. 
2013). This family could represent a new autosomal recessive form of DBA. 
MCM2 (3q21) is a part of the highly conserved mini-chromosome maintenance proteins 
(MCM) that are involved in the initiation of eukaryotic genome replication (Simon and 
Schwacha 2014). It forms a complex with MCM4, MCM6 and MCM7 and regulates the 
helicase activity of the complex. This protein is phosphorylated, and thus regulated by 
protein kinases CDC2 and CDC7 (Simon and Schwacha 2014).  
RNA-Seq analysis of normal erythroid cells at defined stages of differentiation revealed 
that MCM2 mRNA levels are low in CD34+ progenitor cells, increase significantly in BFU-
E, CFU-E, pro-erythroblasts, early and late basophilic erythroblasts, then decrease 
significantly in polychromatic and orthochromatic erythroblasts (O’Brien et al. 2013). 
O’Brien et al., demonstrated that MCM2 depletion resulted in significant reductions in the 
number of CD41-/CD235+ erythroid cells, indicating that this gene play an important role 
in erythropoiesis. Furthermore, when MCM2 downregulated CD34+ cells were plated in 
semi-solid medium, CFU-GM colony numbers were normal, but BFU-E colony formation 
was significantly reduced, suggesting an erythroid specific role for MCM2 (O’Brien et al. 
2013). 
The same authors found two heterozygous MCM2 SNVs (single nucleotide variations) 
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(exon7:c.G1186A:p.A396T and exon13:c.G2179A:p.A727T) in 2 out of 40 American 
sporadic patients with DBA (Bodine & Farrar, personal communication). These variants 
were predicted to be deleterious by the following considerations: analysis of prediction 
tools. 
Interestingly, a previous paper of our group showed that RPS19 interacts with MCM2 and  
with the other components of the DNA helicase complex (MCM6 and MCM7) (Orru et al. 
2007). We also found that this interaction is lost for RPS19 mutants (Caterino et al. 2014). 
Two DBA missense mutations (R62W and R101H) were used in this assay (Caterino et al. 
2014). Overall, these results suggested the contribution of this complex in RPS19 function. 
 
WBSCR22  
 
The human WBSCR22 gene is located in Williams-Beuren Syndrome (WBS) critical region 
on chromosome 7q11, 23 and consists of 13 exons (Doll and Grzeschik 2001). WBS is a 
multisystem developmental disorder associated with hemizygous deletion of a ~1.6 Mb 
region in the given locus (Doll and Grzeschik 2001). The WBS region contains more than 
25 genes and the deletion of this region results in haploinsufficiency of WBS control region 
transcripts (Merla et al. 2006). WBS patients display multiple clinical symptoms including 
cardiovascular malformations, connective tissue abnormalities, intellectual disability 
(usually mild), growth and endocrine abnormalities (Schubert 2009).  
Different studies showed that the WBSCR22 expression is upregulated in different cancer 
types, including invasive breast cancer, multiple myeloma cells and hepatocellular 
carcinoma. Moreover, it was demonstrated that the cell growth is inhibited by treatment 
with WBSCR22 siRNA (Nakazawa, Arai, and Fujita 2011; Tiedemann et al. 2012).  
WBS patients’ lymphoblastoid cell lines show a reduction approximately 2.5 fold of 
WBSCR22 protein level compared to healthy controls (Ounap et al. 2013). However, it is 
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currently not known whether this decrease has any contribution to the development of the 
disorder.  
Five recent works identified WBSCR22 as a key player in ribosome biogenesis (Ounap et 
al. 2013; Ounap et al. 2015; Zorbas et al. 2015; Haag, Kretschmer, and Bohnsack 2015; 
Letoquart et al. 2014). The human WBSCR22 protein is a 18S rRNA methyltransferase 
involved in pre-rRNA processing and ribosome 40S subunit biogenesis. Recent studies 
have shown that the role of WBSCR22 in 40S subunit biogenesis is independent on its 
function as an rRNA methyltransferase (Zorbas et al. 2015). Indeed, the protein itself, rather 
than its enzymatic activity, is required for small ribosomal subunit synthesis. Knockdown 
of WBSCR22 in human cells resulted in accumulation of nuclear pre-rRNA 18SE and a 
reduced level of free 40S ribosomal subunit (Ounap et al. 2013) (Figure 17).   
 
 
 
Figure 17. (B) Northern Blot analysis of HeLa (lanes 1-6) and HEK293 (lanes 7, 8) cells transfected with 
siWBSCR22 or siNeg. with the 5’-ITS1 probe. RNA was extracted 72 h after transfection and 3 μg of total 
(T), 6 μg of cytoplasmic (C) and 3 μg of nuclear (N) RNA were loaded on each lane. Lanes 7 and 8 show 
nuclear RNA. The positions of precursor rRNAs are indicated (Ounap et al. 2013). 
 
I reasoned that this gene could represent a good candidate for DBA patients, that showed a 
similar rRNA precursor pattern. I also considered that the complex clinical phenotype of 
WBS could not be compared to that of DBA, because it was due to a large chromosomal 
deletion encompassing more than 25 genes. 
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Sanger sequencing 
 
Genomic DNA was isolated from peripheral blood with standard procedure and analysed 
for MCM2 and WBSCR22. All the 16 MCM2 and the 13 WBSCR22 exons were screened for 
mutations using standard PCR-based Sanger sequencing. Coding sequences and exon-
intron boundaries were PCR amplified using Go Taq® Flexi DNA Polymerase (Promega). 
The same set of primers was used for both PCR amplification from genomic DNAs and for 
Sanger sequencing (IGA Technology Services). Primer sequences are shown in Table 7 and 
Table 8. Results were analysed using Chromas Lite 2.1.1. Sequences were read by aligning 
with the reference sequence, using the LALIGN tool. 
 
In silico analysis 
 
Allele frequency for each SNV was evaluated using 1000 Genomes Project, ExAC and ESP  
databases. Disease-causing potential was analyzed using six different prediction tools 
(Mutation taster, SIFT, Provean, Polyphen-2, Mutation assessor, Phyre2). The wild type 
sequence conservation was reported as a GERP (Genomic Evolutionary Rate Profiling) 
score as reported on ESP database (GERP score ranges from -12.3 to 6.17, with 6.17 being 
the most conserved).  
Splice site prediction for each SNV was assessed using seven different tools (Human 
Splicing Finder, MaxEnt, BDGP, NetGene2, GeneScan, FGENESH 2.6, FSPLICE 1.0). 
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EXON 1 F:CTCCGTGTCCCTTCTGGTC; R:CCAGGTCAGTGGTAGGTAGGC 
EXON 2 F:AGAGAAAGAAGGGAAGGCCC; R:AATGCCATCGATTCATCTGC 
EXON 3 F:GAACCTTAGGGAACAGGCCC; R:AAGAGACACCTGCTACTGCGG 
EXON 4 F:GAAGCTGGGAAGGAGTCTGG; R:TCACGTGTTCACTCGGCTC 
EXON 5 F:GGTAGGCCTTGCTTCTCACAC; R:AATCGCTCTTCAGGAATCACG 
EXON 6 F:GTGTGTTGGGACACTCTCGTC; R:CACACTGGTCTTCCACAGCC 
EXON 7 F:ATTCCTTGCTGTCTTTGGCTC; R:AAACAGATCCTAGCCCGAGTG 
EXON 8 F:GTGTGGAGCACTTGCAATAGG; R:TAAGGCAAGGTTTGAGCAGTG 
EXON 9 F:CTGTGGAAGTGGGTGTCTTTG; R:CCTTGAAGAATGAGTCACGCC 
EXON 10 F:AGGGACTGTGCCTTACCATTC; R:CATTAACACCATTCCCGTCG 
EXON 11 F:CGACGGGAATGGTGTTAATG; R:CTGCTGCACAATGACTTCCTC 
EXON 12 F:ATGTCTTCCTCTTCCACTGCC; R:GGACATGAGAAGAGACCGAGG  
EXON 13 F:CTTCTCCAGCCACTGACCTC; R:TTTAATGCCTCCCTGCTCTG 
EXON 14 F:AGATGGGTCTTCTTGGCTCTG; R:CCACACTCCCTTTACCCTACG 
EXON 15 F:GTGCTGGCACGTAGGGTAAAG; R:TAAATGGCTGTCAACCAAGGC 
EXON 16 F:GGTGATGGTGTCTGAAAGTGC; R:AGCGGAAGTCCAGGTTACTTAC 
 
Table 7: MCM2 primers sequences used for PCR amplification and Sanger sequencing. B) (F: 
Forward primer; R: Reverse primer). 
 
EXON 1-2 F: ATGAGAGGAGTCGGTTGGTC; R: GAGACAGAAATCGGCACC 
EXON 3-4 F:TAGAGCAGCCCAGCCTAAT; R:GGTGCCAGACAGGACATA 
EXON 5 F:AACTGACCCTGAGTGTCTGGT; R: CCTGGTGACAGAGCAAGACTCC 
EXON 6 F: GGACGGATGATGTCAAGAGGC; R: CAGTGCTAGGGAGGGACAG 
EXON 7 F: CAGCCCTAACAATGCCTCAC; R: CTCCTTTTCCCGCCAATCTG 
EXON 8-9 F:CCGCTGCCTTTCTTTCCTCAG; R:CAGTGTTCTCCCAGCAGGCTCTG 
EXON 10 F:GTGGGGCAGATGGTTTGAGAAC; R: GGTGAGGGCAGAGAGAAAGT 
EXON 11-12 F: TGCCCACCCAACAACCTCTGT; R: TCAAAGCAGCCCTGGACCCTTC 
EXON 13 F:CTGTGGAAGTGGGTGTCTTTG; R:CAGCCCAAGACATCCAAGCACTGG 
 
Table 8. WBSCR22 primers sequences used for PCR amplification and Sanger sequencing. (F: 
Forward primer; R: Reverse primer) 
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Results and Discussion 
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The second part of my PhD project was focused on the screening of two new candidate 
DBA genes: MCM2 and WBSCR22.  
For MCM2 screening from the Italian DBA registry we selected a cohort of 53 DBA 
patients (22 females and 32 males) who were already screened for the 7  RP genes (RPS10, 
RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A) that are most frequently mutated in 
DBA patients and for GATA1.   
The only SNV of interest that I found, was a heterozygous change in exon7: c.G1186A: 
p.A396T. This SNV was also found by our US collaborators in a single US patient out of 
40. Overall, this SNV was found in 2 out of 93 DBA patients with an allele frequency of 
0,01.  
This SNV was reported in the 1000genomes project with an allele frequency of 0.008 in the 
European population. The ExAC database reported an allele frequency of 0.01 in the 
European population. Similarly the ESP database reported an allele frequency of 0.01 
referred to European-American population. This allele frequency is consistent with a 
common polymorphism. 
The prediction algorithms reported the following outputs: 
 
SIFT Damaging 
PolyPhen-2 Possibly damaging 
Mutation Assessor Function impact medium 
Mutation Tasting Disease causing 
Provean Neutral 
Phyre 2 Unlikely to affect function 
 
The wild type sequence is conserved across the species being GERP score 5.31.  
Missense variants may modify splicing. Human Splicing Finder showed that this SNV 
disrupts an Exonic Splicing Regulatory Sequence (Goren et al.). 
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This SNV did not affect any functional domain of MCM2 (Figure 18). 
 
 
 
Figure 18. Conserved domains on MCM2 protein sequence (Marchler-Bauer et al. 2015). 
 
We also decided to analyze the proband’s parents who did not show any symptoms of 
anemia. Sanger sequencing on the parents revealed that SNV of interest was inherited from 
the proband’s mother (Figure 19).  
In conclusion, this SNV could be considered as a VUS (Variant of Unknown Significance).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
90
  
 
 
PROBAND 
 
 
 
MOTHER 
 
 
 
FATHER 
 
 
Figure 19. Electropherogram  showing c.1186G>A within MCM2 gene in the proband and 
parents. 
 
This patient was subsequently evaluated by rRNA processing by Bioanalyzer. The 
identification of rRNA 28S/18S ratio of 1,2 and the presence of a peak corresponding to 
G/G 
G/A 
G/A 
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pre-rRNA 32S (Emanuela Garelli, Department of Public Health and Paediatric Sciences, 
University of Turin, personal communication) induced a reassessment of the patient’s 
sequencing data. This finding suggested the impairment of a ribosomal protein of the large 
subunit. Thus, resequencing of RPL genes was performed in the proband. This led to the 
discovery of splicing variant in RPL5: c.3+5G>A (Emanuela Garelli, personal 
communication). Analysis of splice site prediction tools (see Methods) revealed that this 
SNV alters the wild type donor site, most probably affecting splicing. 
Taking into account rRNA analysis, this SNV is considered as pathogenic.   
 
In conclusion, our results do not either support or deny a role for MCM2 in DBA, because 
we have not found any patients with homozygous or compound heterozygous mutations 
and the effect of the single VUS we found needs to be studied in a functional assay. 
 
Analysis of WBSCR22 showed a SNV in the third intron c.256-11A>G. Analysis of this 
variant by different splice site prediction tools (see Methods) did not predict any splicing 
alteration. In conclusion, our results do not show a role for WBSCR22 at least in the single 
patient that was tested, that showed a suggestive rRNA precursor accumulation. 
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6. Conclusions 
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The difficulties in clinical diagnosis of DBA and the absence of specific assays were the 
main focus of my PhD thesis. With the aim to establish a simple and routine test which 
might support the diagnosis, I turned to the study of EVs. This was an innovative approach 
since no data were available on erythroid progenitors derived EVs. We reasoned that EVs 
might alter their properties in response to the reduced number of erythroid progenitors in 
BM patients’. Among the different erythroid EV populations we found, the only one able to 
distinguish between DBA patients and the other groups under study was the 
CD34+/CD71low population. Our finding is in agreement with the low number of BFU-E 
progenitors in the BM of patients. 
The method we devised is reproducible, sensitive and easily translatable to laboratory 
routine. It should be noted that this assay is performed from peripheral blood, is amenable 
to transfused patients and requires only two working days, whereas BFU-E cultures require 
15 working days and need to be performed using a bone marrow sample in DBA patients. 
 
The second aim of my project was to analyze to new candidate DBA genes. Although 
preliminary data strongly suggested MCM2 as potential causative gene for DBA, our results 
were not conclusive. 
  
Since the downregulation of WBSCR22 leads to an accumulation of pre-rRNA 18SE, we 
screened this gene in a patient with the same rRNA phenotype by Northern Blot, but no 
sequence variation was found.  
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7. Future Perspectives 
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We propose to use our EV-based assay to support the diagnosis of new suspected DBA 
patients. 
It should be interesting to analyze the same membrane markers in peripheral blood cells but 
this would be hampered by the reduced number of these cells in peripheral blood. 
The recent immunophenotypic characterization of each stage of erythroid differentiation 
paved the way to many applications. In this point of view, we could implement our markers 
panel to individuate other interesting EVs subpopulations. 
This assay could be a useful tool to select erythroid cell-derived EVs in order to study their 
content and their functional role in erythroid differentiation. 
Finally, it may also be modified to isolate EVs derived by other lineage specific progenitors 
and used to study other types of bone marrow failure syndromes. 
 
In the future all the DBA patients with an unusual rRNA precursor pattern should be 
studied by exome or whole genome sequencing. 
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